{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:46:55Z","timestamp":1789580815841,"version":"build-2803163510"},"reference-count":233,"publisher":"Bentham Science Publishers Ltd.","issue":"9","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>:<\/jats:title>\n                    <jats:p>Lung cancer remains a significant contributor to cancer mortality for several reasons.\nFirst, lung cancer is a molecularly heterogeneous disease. When combined with the dramatic resistance\nto treatment mediated by a tumor microenvironment (TME) that is inherently immunosuppressive,\nthis explains the continued high mortality associated with lung cancer. The new era of\ntreating non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), as well as achieving\nlong-lasting treatment responses, is driven by immune checkpoint inhibitors (ICIs) targeting PD-\n1, PD-L1, and CTLA-4. This treatment revolution may, in the future, be applied to isolated cases of\nrelapse and recurrent disease, resulting in sustained therapeutic responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>:<\/jats:title>\n                    <jats:p>In this review, we outline recent advances, including novel agent combinations and combination\nregimens tested in clinical trials that have become milestones, such as Nivolumab, Pembrolizumab,\nDurvalumab, and emerging bispecific combinations. Targeted therapeutic delivery is now possible\nthrough nanotechnology and biomaterials, such as polymer nanoparticles and smart hydrogels,\nwhich allow high local drug concentration at the tumor site while reducing systemic toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>:<\/jats:title>\n                    <jats:p>Predictive biomarkers, including PD-L1 expression, tumor mutational burden (TMB), circulating\ntumor DNA (ctDNA), and radiomic features, are increasingly used to select patients and assess\ntreatment responses in real time. Despite these advances, resistance to immunotherapy and immunerelated\nadverse events (irAEs) remain major challenges, emphasizing the need for ongoing innovation\nin personalized management, toxicity mitigation, and treatment strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>:<\/jats:title>\n                    <jats:p>Industry leaders are now exploring artificial intelligence to optimize treatment selection and predict\nadverse events and outcomes early. Ultimately, improved survival rates and enhanced patient experiences\nmay be achieved through the integration of novel biomarkers, precision technologies, and\nmore effective immunotherapies for lung cancer patients. Significant research is still required to\novercome resistance mechanisms, optimize combination therapies, and enable individualized care in\nthis rapidly advancing field<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113895575415429251007093531","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:09:51Z","timestamp":1761894591000},"page":"669-696","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Unlocking the Immune System: Advances in Next-generation Immunotherapy for Lung Cancer"],"prefix":"10.2174","volume":"26","author":[{"given":"Furqan","family":"Choudhary","sequence":"first","affiliation":[{"name":"Department of Biotechnology, Jamia Hamdard, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman","family":"Safdar","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Jamia Hamdard, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malik Zainul","family":"Abdin","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Jamia Hamdard, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humaira","family":"Farooqi","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Jamia Hamdard, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-024-01581-2","volume":"17","author":"Cheng W.","year":"2024","unstructured":"Cheng W.; Kang K.; Zhao A.; Wu Y.; Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer. J Hematol Oncol  2024,17(1),54","journal-title":"J Hematol Oncol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1200\/JCO.2005.04.8595","volume":"24","author":"Hanna N.","year":"2006","unstructured":"Hanna N.; Bunn P.A.; Langer C.; Einhorn L.; Guthrie T.; Beck T.; Ansari R.; Ellis P.; Byrne M.; Morrison M.; Hariharan S.; Wang B.; Sandler A.; Randomized phase III trial comparing irinotecan\/cisplatin with etoposide\/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol  2006,24(13),2038-2043","journal-title":"J Clin Oncol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/annonc\/mdw326","volume":"27","author":"Novello S.","year":"2016","unstructured":"Novello S.; Barlesi F.; Califano R.; Cufer T.; Ekman S.; Levra M. G.; Kerr K.; Popat S.; Reck M.; Senan S.; Simo G. V.; Vansteenkiste J.; Peters S.; Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol  2016,27(Suppl. 5),v1-v27","journal-title":"Ann Oncol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.bbcan.2015.08.002","volume":"1856","author":"Lemjabbar-Alaoui H.","year":"2015","unstructured":"Lemjabbar-Alaoui H.; Hassan O. U. I.; Yang Y. W.; Buchanan P.; Lung cancer: Biology and treatment options.. Biochim Biophys Acta Rev Cancer  2015,1856(2),189-210","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40364-020-00212-5","volume":"8","author":"Sun J. Y.","year":"2020","unstructured":"Sun J. Y.; Zhang D.; Wu S.; Xu M.; Zhou X.; Lu X. J.; Ji J.; Resistance to PD-1\/PD-L1 blockade cancer immunotherapy: Mechanisms, predictive factors, and future perspectives. Biomark Res  2020,8(1),35","journal-title":"Biomark Res"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"750657","DOI":"10.3389\/fonc.2021.750657","volume":"11","author":"Seegobin K.","year":"2021","unstructured":"Seegobin K.; Majeed U.; Wiest N.; Manochakian R.; Lou Y.; Zhao Y.; Immunotherapy in non-small cell lung cancer with actionable mutations other than EGFR. Front Oncol  2021,11,750657","journal-title":"Front Oncol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1158\/1078-0432.CCR-13-0731","volume":"20","author":"Forde P.M.","year":"2014","unstructured":"Forde P.M.; Kelly R.J.; Brahmer J.R.; New strategies in lung cancer: Translating immunotherapy into clinical practice.. Clin Cancer Res  2014,20(5),1067-1073","journal-title":"Clin Cancer Res"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"Pardoll D. M.","year":"2012","unstructured":"Pardoll D. M.; The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer  2012,12(4),252-264","journal-title":"Nat Rev Cancer"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"Ribas A.","year":"2018","unstructured":"Ribas A.; Wolchok J. D.; Cancer immunotherapy using checkpoint blockade. Science  2018,359(6382),1350-1355","journal-title":"Science"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","volume":"39","author":"Buchbinder E. I.","year":"2016","unstructured":"Buchbinder E. I.; Desai A.; CTLA-4 and PD-1 pathways: Similarities, differences, and implications of their inhibition. Am J Clin Oncol  2016,39(1),98-106","journal-title":"Am J Clin Oncol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.it.2008.02.011","volume":"29","author":"Valk E.","year":"2008","unstructured":"Valk E.; Rudd C. E.; Schneider H.; CTLA-4 trafficking and surface expression.. Trends Immunol  2008,29(6),272-279","journal-title":"Trends Immunol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/imm.13871","volume":"174","author":"Aden D.","year":"2025","unstructured":"Aden D.; Sureka N.; Zaheer S.; Chaurasia J. K.; Zaheer S.; Metabolic reprogramming in cancer: Implications for immunosuppressive microenvironment.. Immunology  2025,174(1),30-72","journal-title":"Immunology"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"513","DOI":"10.14348\/molcells.2022.2056","volume":"45","author":"Kim G. R.","year":"2022","unstructured":"Kim G. R.; Choi J. M.; Current understanding of cytotoxic T Lymphocyte Antigen-4 (CTLA-4) signaling in T-cell biology and disease therapy. Mol Cells  2022,45(8),513-521","journal-title":"Mol Cells"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/1074-7613(94)90071-X","volume":"1","author":"Walunas T. L.","year":"1994","unstructured":"Walunas T. L.; Lenschow D. J.; Bakker C. Y.; Linsley P. S.; Freeman G. J.; Green J. M.; Thompson C. B.; Bluestone J. A.; CTLA-4 can function as a negative regulator of T cell activation. Immunity  1994,1(5),405-413","journal-title":"Immunity"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1126\/science.1160062","volume":"322","author":"Wing K.","year":"2008","unstructured":"Wing K.; Onishi Y.; Prieto-Martin P.; Yamaguchi T.; Miyara M.; Fehervari Z.; Nomura T.; Sakaguchi S.; CTLA-4 control over Foxp3+ regulatory T cell function.. Science  2008,322(5899),271-275","journal-title":"Science"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S1074-7613(94)80021-9","volume":"1","author":"Linsley P.S.","year":"1994","unstructured":"Linsley P.S.; Greene J.L.; Brady W.; Bajorath J.; Ledbetter J.A.; Peach R.; Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity  1994,1(9),793-801","journal-title":"Immunity"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1084\/jem.174.3.561","volume":"174","author":"Linsley P. S.","year":"1991","unstructured":"Linsley P. S.; Brady W.; Urnes M.; Grosmaire L. S.; Damle N. K.; Ledbetter J. A.; CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med  1991,174(3),561-569","journal-title":"J Exp Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.1073\/pnas.87.13.5031","volume":"87","author":"Linsley P. S.","year":"1990","unstructured":"Linsley P. S.; Clark E. A.; Ledbetter J. A.; T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7\/BB-1. Proc Natl Acad Sci USA  1990,87(13),5031-5035","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1084\/jem.182.2.459","volume":"182","author":"Krummel M. F.","year":"1995","unstructured":"Krummel M. F.; Allison J. P.; CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.. J Exp Med  1995,182(2),459-465","journal-title":"J Exp Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.3390\/cancers12071760","volume":"12","author":"Cornel A.M.","year":"2020","unstructured":"Cornel A.M.; Mimpen I.L.; Nierkens S.; MHC class I downregulation in cancer: Underlying mechanisms and potential targets for cancer immunotherapy. Cancers  2020,12(7),1760","journal-title":"Cancers"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"636568","DOI":"10.3389\/fimmu.2021.636568","volume":"12","author":"Dhatchinamoorthy K.","year":"2021","unstructured":"Dhatchinamoorthy K.; Colbert J.D.; Rock K.L.; Cancer immune evasion through loss of MHC class I antigen presentation. Front Immunol  2021,12,636568","journal-title":"Front Immunol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"21442","DOI":"10.3389\/FIMMU.2012.00051\/BIBTEX","volume":"3","author":"Schmidt A.","year":"2012","unstructured":"Schmidt A.; Oberle N.; Krammer P.H.; Molecular mechanisms oftreg-mediatedt cell suppression. Front Immunol  2012,3(MAR),21442","journal-title":"Front Immunol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.immuni.2009.04.010","volume":"30","author":"Shevach E.M.","year":"2009","unstructured":"Shevach E.M.; Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity  2009,30(5),636-645","journal-title":"Immunity"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coi.2013.12.005","volume":"27","author":"Nishikawa H.","year":"2014","unstructured":"Nishikawa H.; Sakaguchi S.; Regulatory T cells in cancer immunotherapy. Curr Opin Immunol  2014,27(1),1-7","journal-title":"Curr Opin Immunol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/vaccines4030028","volume":"4","author":"Chaudhary B.","year":"2016","unstructured":"Chaudhary B.; Elkord E.; Regulatory T cells in the tumor microenvironment and cancer progression: Role and therapeutic targeting. Vaccines  2016,4(3),28","journal-title":"Vaccines"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1517\/14712598.2010.529126","volume":"10","author":"Elkord E.","year":"2010","unstructured":"Elkord E.; Alcantar-Orozco E. M.; Dovedi S. J.; Tran D. Q.; Hawkins R. E.; Gilham D. E.; T regulatory cells in cancer: Recent advances and therapeutic potential.. Expert Opin Biol Ther  2010,10(11),1573-1586","journal-title":"Expert Opin Biol Ther"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"2023739118","DOI":"10.1073\/pnas.2023739118","volume":"118","author":"Tekguc M.","year":"2021","unstructured":"Tekguc M.; Wing J.B.; Osaki M.; Long J.; Sakaguchi S.; Treg-expressed CTLA-4 depletes CD80\/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells. Proc Natl Acad Sci USA  2021,118(30),2023739118","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.3389\/fimmu.2019.02453","volume":"10","author":"Paluskievicz C.M.","year":"2019","unstructured":"Paluskievicz C.M.; Cao X.; Abdi R.; Zheng P.; Liu Y.; Bromberg J.S.; T regulatory cells and priming the suppressive tumor microenvironment.. Front Immunol  2019,10(OCT),2453","journal-title":"Front Immunol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12943-024-02156-y","volume":"23","author":"Zhang A.","year":"2024","unstructured":"Zhang A.; Fan T.; Liu Y.; Yu G.; Li C.; Jiang Z.; Regulatory T cells in immune checkpoint blockade antitumor therapy. Mol Cancer  2024,23(1),251","journal-title":"Mol Cancer"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/PAI.0000000000001181","volume":"32","author":"Abdelrahman D. I.","year":"2024","unstructured":"Abdelrahman D. I.; Elhasadi I.; Anbaig A.; Bakry A.; Mandour D.; Wasefy T.; Yehia A. M.; Alorini M.; Shalaby A. M.; Yahia A. I. O.; Alabiad M. A.; Immunohistochemical expression of immune checkpoints; CTLA-4, LAG3, and TIM-3 in cancer cells and tumor-infiltrating Lymphocytes (TILs) in colorectal carcinoma.. Appl Immunohistochem Mol Morphol  2024,32(2),71-83","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1080\/21645515.2015.1129478","volume":"12","author":"Savoia P.","year":"2016","unstructured":"Savoia P.; Astrua C.; Fava P.; Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management.. Hum Vaccin Immunother  2016,12(5),1092-1101","journal-title":"Hum Vaccin Immunother"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/cam4.371","volume":"4","author":"Camacho L. H.","year":"2015","unstructured":"Camacho L. H.; CTLA\u20104 blockade with ipilimumab: Biology, safety, efficacy, and future considerations. Cancer Med  2015,4(5),661-672","journal-title":"Cancer Med"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1158\/1078-0432.CCR-18-0762","volume":"25","author":"Sharma A.","year":"2019","unstructured":"Sharma A.; Subudhi S. K.; Blando J.; Scutti J.; Vence L.; Wargo J.; Allison J. P.; Ribas A.; Sharma P.; Anti-CTLA-4 immunotherapy does not deplete Foxp3 \u00fe regulatory T cells (Tregs) in human cancers.. Clin Cancer Res  2019,25(4),1233-1238","journal-title":"Clin Cancer Res"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"Wolchok J. D.","year":"2013","unstructured":"Wolchok J. D.; Kluger H.; Callahan M. K.; Postow M. A.; Rizvi N. A.; Lesokhin A. M.; Segal N. H.; Ariyan C. E.; Gordon R. A.; Reed K.; Burke M. M.; Caldwell A.; Kronenberg S. A.; Agunwamba B. U.; Zhang X.; Lowy I.; Inzunza H. D.; Feely W.; Horak C. E.; Hong Q.; Korman A. J.; Wigginton J. M.; Gupta A.; Sznol M.; Nivolumab plus ipilimumab in advanced melanoma.. N Engl J Med  2013,369(2),122-133","journal-title":"N Engl J Med"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1200\/jco.2013.31.15_suppl.3061","volume":"31","author":"Selby M.","year":"2013","unstructured":"Selby M.; Engelhardt J.; Lu L-S.; Quigley M.; Wang C.; Chen B.; Korman A.J.; Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models.. J Clin Oncol  2013,31(15_suppl),3061-3061","journal-title":"J Clin Oncol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"Postow M. A.","year":"2015","unstructured":"Postow M. A.; Chesney J.; Pavlick A. C.; Robert C.; Grossmann K.; McDermott D.; Linette G. P.; Meyer N.; Giguere J. K.; Agarwala S. S.; Shaheen M.; Ernstoff M. S.; Minor D.; Salama A. K.; Taylor M.; Ott P. A.; Rollin L. M.; Horak C.; Gagnier P.; Wolchok J. D.; Hodi F. S.; Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med  2015,372(21),2006-2017","journal-title":"N Engl J Med"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1073\/pnas.0915174107","volume":"107","author":"Curran M. A.","year":"2010","unstructured":"Curran M. A.; Montalvo W.; Yagita H.; Allison J. P.; PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA  2010,107(9),4275-4280","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.2147\/DDDT.S267433","volume":"14","author":"Ai L.","year":"2020","unstructured":"Ai L.; Chen J.; Yan H.; He Q.; Luo P.; Xu Z.; Yang X.; Research status and outlook of pd-1\/pd-l1 inhibitors for cancer therapy. Drug Des Devel Ther  2020,14,3625-3649","journal-title":"Drug Des Devel Ther"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.7150\/jca.57334","volume":"12","author":"Ghosh C.","year":"2021","unstructured":"Ghosh C.; Luong G.; Sun Y.; A snapshot of the PD-1\/PD-L1 pathway. J Cancer  2021,12(9),2735-2746","journal-title":"J Cancer"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.3390\/ijms22105123","volume":"22","author":"Munari E.","year":"2021","unstructured":"Munari E.; Mariotti F.R.; Quatrini L.; Bertoglio P.; Tumino N.; Vacca P.; Eccher A.; Ciompi F.; Brunelli M.; Martignoni G.; Bogina G.; Moretta L.; PD-1\/PD-L1 in Cancer: Pathophysiological, diagnostic and therapeutic aspects. Int J Mol Sci  2021,22(10),5123","journal-title":"Int J Mol Sci"},{"key":"ref=41","first-page":"727","volume":"10","author":"Han Y.","year":"2020","unstructured":"Han Y.; Liu D.; Li L.; PD-1\/PD-L1 pathway: Current researches in cancer.. Am J Cancer Res  2020,10(3),727-742","journal-title":"Am J Cancer Res"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"790963","DOI":"10.3389\/fphar.2021.790963","volume":"12","author":"Singh V.","year":"2021","unstructured":"Singh V.; Khurana A.; Allawadhi P.; Banothu A.K.; Bharani K.K.; Weiskirchen R.; Emerging role of PD-1\/PD-L1 inhibitors in chronic liver diseases. Front Pharmacol  2021,12,790963","journal-title":"Front Pharmacol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"100738","DOI":"10.1016\/j.tranon.2019.12.010","volume":"13","author":"Barrueto L.","year":"2020","unstructured":"Barrueto L.; Caminero F.; Cash L.; Makris C.; Lamichhane P.; Deshmukh R.R.; Resistance to checkpoint inhibition in cancer immunotherapy.. Transl Oncol  2020,13(3),100738","journal-title":"Transl Oncol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"173240","DOI":"10.1016\/j.ejphar.2020.173240","volume":"881","author":"Yu X.","year":"2020","unstructured":"Yu X.; Gao R.; Li Y.; Zeng C.; Regulation of PD-1 in T cells for cancer immunotherapy.. Eur J Pharmacol  2020,881,173240","journal-title":"Eur J Pharmacol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1296341","DOI":"10.3389\/fimmu.2023.1296341","volume":"14","author":"Parvez A.","year":"2023","unstructured":"Parvez A.; Choudhary F.; Mudgal P.; Khan R.; Qureshi K. A.; Farooqi H.; Aspatwar A.; PD-1 and PD-L1: Architects of immune symphony and immunotherapy breakthroughs in cancer treatment. Front Immunol  2023,14,1296341","journal-title":"Front Immunol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"114215","DOI":"10.1016\/j.biopha.2023.114215","volume":"159","author":"Liu X.","year":"2023","unstructured":"Liu X.; Yang L.; Tan X.; PD-1\/PD-L1 pathway: A double-edged sword in periodontitis.. Biomed Pharmacother  2023,159,114215","journal-title":"Biomed Pharmacother"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-981-15-3266-5_3","volume":"1248","author":"Ai L.","year":"2020","unstructured":"Ai L.; Xu A.; Xu J.; Roles of PD-1\/PD-L1 pathway: Signaling, cancer, and beyond. Adv Exp Med Biol  2020,1248,33-59","journal-title":"Adv Exp Med Biol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-020-01027-5","volume":"14","author":"Yi M.","year":"2021","unstructured":"Yi M.; Niu M.; Xu L.; Luo S.; Wu K.; Regulation of PD-L1 expression in the tumor microenvironment.. J Hematol Oncol  2021,14(1),10","journal-title":"J Hematol Oncol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3390\/cancers10020032","volume":"10","author":"Abdin S. M.","year":"2018","unstructured":"Abdin S. M.; Zaher D. M.; Arafa E. S. A.; Omar H. A.; Tackling cancer resistance by immunotherapy: Updated clinical impact and safety of PD-1\/PD-L1 inhibitors. Cancers  2018,10(2),32","journal-title":"Cancers"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1080\/17425255.2016.1223047","volume":"12","author":"Wong A. C. Y.","year":"2016","unstructured":"Wong A. C. Y.; Ma B.; An update on the pharmacodynamics, pharmacokinetics, safety and clinical efficacy of nivolumab in the treatment of solid cancers. Expert Opin Drug Metab Toxicol  2016,12(10),1255-1261","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"410","DOI":"10.7150\/jca.17144","volume":"8","author":"Guo L.","year":"2017","unstructured":"Guo L.; Zhang H.; Chen B.; Nivolumab as programmed death-1 (PD-1) inhibitor for targeted immunotherapy in tumor. J Cancer  2017,8(3),410-416","journal-title":"J Cancer"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2147\/TCRM.S78039","volume":"12","author":"Carvajal R. D.","year":"2016","unstructured":"Carvajal R. D.; Asmar R.; Yang J.; Clinical utility of nivolumab in the treatment of advanced melanoma.. Ther Clin Risk Manag  2016,12,313-325","journal-title":"Ther Clin Risk Manag"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/ITT.S110479","volume":"6","author":"Force J.","year":"2017","unstructured":"Force J.; Salama A.; First-line treatment of metastatic melanoma: Role of nivolumab. ImmunoTargets Ther  2017,6,1-10","journal-title":"ImmunoTargets Ther"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1517\/14712598.2016.1141195","volume":"16","author":"Spain L.","year":"2016","unstructured":"Spain L.; Larkin J.; Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma. Expert Opin Biol Ther  2016,16(3),389-396","journal-title":"Expert Opin Biol Ther"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s10637-016-0411-2","volume":"35","author":"Yamamoto N.","year":"2017","unstructured":"Yamamoto N.; Nokihara H.; Yamada Y.; Shibata T.; Tamura Y.; Seki Y.; Honda K.; Tanabe Y.; Wakui H.; Tamura T.; Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors. Invest New Drugs  2017,35(2),207-216","journal-title":"Invest New Drugs"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","volume":"28","author":"Brahmer J. R.","year":"2010","unstructured":"Brahmer J. R.; Drake C. G.; Wollner I.; Powderly J. D.; Picus J.; Sharfman W. H.; Stankevich E.; Pons A.; Salay T. M.; McMiller T. L.; Gilson M. M.; Wang C.; Selby M.; Taube J. M.; Anders R.; Chen L.; Korman A. J.; Pardoll D. M.; Lowy I.; Topalian S. L.; Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol  2010,28(19),3167-3175","journal-title":"J Clin Oncol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1080\/14712598.2018.1478962","volume":"18","author":"Zarrabi K.","year":"2018","unstructured":"Zarrabi K.; Wu S.; An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma. Expert Opin Biol Ther  2018,18(6),695-705","journal-title":"Expert Opin Biol Ther"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.tripleo.2011.05.011","volume":"113","author":"Fatahzadeh M.","year":"2012","unstructured":"Fatahzadeh M.; Kaposi sarcoma: Review and medical management update. Oral Surg Oral Med Oral Pathol Oral Radiol  2012,113(1),2-16","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","volume":"32","author":"Topalian S. L.","year":"2014","unstructured":"Topalian S. L.; Sznol M.; McDermott D. F.; Kluger H. M.; Carvajal R. D.; Sharfman W. H.; Brahmer J. R.; Lawrence D. P.; Atkins M. B.; Powderly J. D.; Leming P. D.; Lipson E. J.; Puzanov I.; Smith D. C.; Taube J. M.; Wigginton J. M.; Kollia G. D.; Gupta A.; Pardoll D. M.; Sosman J. A.; Hodi F. S.; Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol  2014,32(10),1020-1030","journal-title":"J Clin Oncol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","volume":"5","author":"Topalian S. L.","year":"2019","unstructured":"Topalian S. L.; Hodi F. S.; Brahmer J. R.; Gettinger S. N.; Smith D. C.; McDermott D. F.; Powderly J. D.; Sosman J. A.; Atkins M. B.; Leming P. D.; Spigel D. R.; Antonia S. J.; Drilon A.; Wolchok J. D.; Carvajal R. D.; McHenry M. B.; Hosein F.; Harbison C. T.; Grosso J. F.; Sznol M.; Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non\u2013small cell lung cancer treated With Nivolumab. JAMA Oncol  2019,5(10),1411-1420","journal-title":"JAMA Oncol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"Topalian S. L.","year":"2012","unstructured":"Topalian S. L.; Hodi F. S.; Brahmer J. R.; Gettinger S. N.; Smith D. C.; McDermott D. F.; Powderly J. D.; Carvajal R. D.; Sosman J. A.; Atkins M. B.; Leming P. D.; Spigel D. R.; Antonia S. J.; Horn L.; Drake C. G.; Pardoll D. M.; Chen L.; Sharfman W. H.; Anders R. A.; Taube J. M.; McMiller T. L.; Xu H.; Korman A. J.; Jure-Kunkel M.; Agrawal S.; McDonald D.; Kollia G. D.; Gupta A.; Wigginton J. M.; Sznol M.; Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med  2012,366(26),2443-2454","journal-title":"N Engl J Med"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1586\/14737140.2016.1123626","volume":"16","author":"Dang T. O.","year":"2016","unstructured":"Dang T. O.; Ogunniyi A.; Barbee M. S.; Drilon A.; Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer.. Expert Rev Anticancer Ther  2016,16(1),13-20","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"Garon E. B.","year":"2015","unstructured":"Garon E. B.; Rizvi N. A.; Hui R.; Leighl N.; Balmanoukian A. S.; Eder J. P.; Patnaik A.; Aggarwal C.; Gubens M.; Horn L.; Carcereny E.; Ahn M. J.; Felip E.; Lee J. S.; Hellmann M. D.; Hamid O.; Goldman J. W.; Soria J. C.; Dolled-Filhart M.; Rutledge R. Z.; Zhang J.; Lunceford J. K.; Rangwala R.; Lubiniecki G. M.; Roach C.; Emancipator K.; Gandhi L.; Pembrolizumab for the treatment of non-small-cell lung cancer.. N Engl J Med  2015,372(21),2018-2028","journal-title":"N Engl J Med"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","volume":"12","author":"Kwok G.","year":"2016","unstructured":"Kwok G.; Yau T. C. C.; Chiu J. W.; Tse E.; Kwong Y. L.; Pembrolizumab (Keytruda). Hum Vaccin Immunother  2016,12(11),2777-2789","journal-title":"Hum Vaccin Immunother"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1517\/14712598.2016.1145652","volume":"16","author":"Lim S. H.","year":"2016","unstructured":"Lim S. H.; Sun J. M.; Lee S. H.; Ahn J. S.; Park K.; Ahn M. J.; Pembrolizumab for the treatment of non-small cell lung cancer. Expert Opin Biol Ther  2016,16(3),397-406","journal-title":"Expert Opin Biol Ther"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1080\/14712598.2018.1522300","volume":"18","author":"Ninomiya K.","year":"2018","unstructured":"Ninomiya K.; Hotta K.; Pembrolizumab for the first-line treatment of non-small cell lung cancer.. Expert Opin Biol Ther  2018,18(10),1015-1021","journal-title":"Expert Opin Biol Ther"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"Reck M.","year":"2016","unstructured":"Reck M.; Rodr\u00edguez-Abreu D.; Robinson A. G.; Hui R.; Cs\u0151szi T.; F\u00fcl\u00f6p A.; Gottfried M.; Peled N.; Tafreshi A.; Cuffe S.; O'Brien M.; Rao S.; Hotta K.; Leiby M. A.; Lubiniecki G. M.; Shentu Y.; Rangwala R.; Brahmer J. R.; Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer. N Engl J Med  2016,375(19),1823-1833","journal-title":"N Engl J Med"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1634\/theoncologist.2017-0078","volume":"22","author":"Pai-Scherf L.","year":"2017","unstructured":"Pai-Scherf L.; Blumenthal G. M.; Li H.; Subramaniam S.; Mishra-Kalyani P. S.; He K.; Zhao H.; Yu J.; Paciga M.; Goldberg K. B.; McKee A. E.; Keegan P.; Pazdur R.; FDA approval summary: Pembrolizumab for treatment of metastatic non-small cell lung cancer: First-line therapy and beyond. Oncologist  2017,22(11),1392-1399","journal-title":"Oncologist"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1093\/annonc\/mdz288","volume":"30","author":"Aguilar E. J.","year":"2019","unstructured":"Aguilar E. J.; Ricciuti B.; Gainor J. F.; Kehl K. L.; Kravets S.; Dahlberg S.; Nishino M.; Sholl L. M.; Adeni A.; Subegdjo S.; Khosrowjerdi S.; Peterson R. M.; Digumarthy S.; Liu C.; Sauter J.; Rizvi H.; Arbour K. C.; Carter B. W.; Heymach J. V.; Altan M.; Hellmann M. D.; Awad M. M.; Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Ann Oncol  2019,30(10),1653-1659","journal-title":"Ann Oncol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1081729","DOI":"10.3389\/fonc.2022.1081729","volume":"12","author":"Felciano J. L.","year":"2023","unstructured":"Felciano J. L.; McLoone D.; Xu Y.; Quek R. G. W.; Kuznik A.; Pouliot J. F.; Gullo G.; Rietschel P.; Guyot P.; Konidaris G.; Chan K.; Keeping S.; Wilson F. R.; Freemantle N.; Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer. Front Oncol  2023,12,1081729","journal-title":"Front Oncol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"925938","DOI":"10.3389\/fonc.2022.925938","volume":"12","author":"Mizuno T.","year":"2022","unstructured":"Mizuno T.; Katsuya Y.; Sato J.; Koyama T.; Shimizu T.; Yamamoto N.; Emerging PD-1\/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China. Front Oncol  2022,12,925938","journal-title":"Front Oncol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","volume":"397","author":"Sezer A.","year":"2021","unstructured":"Sezer A.; Kilickap S.; G\u00fcm\u00fc\u015f M.; Bondarenko I.; \u00d6zg\u00fcro\u011flu M.; Gogishvili M.; Turk H. M.; Cicin I.; Bentsion D.; Gladkov O.; Clingan P.; Sriuranpong V.; Rizvi N.; Gao B.; Li S.; Lee S.; McGuire K.; Chen C. I.; Makharadze T.; Paydas S.; Nechaeva M.; Seebach F.; Weinreich D. M.; Yancopoulos G. D.; Gullo G.; Lowy I.; Rietschel P.; Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: A multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet  2021,397(10274),592-604","journal-title":"Lancet"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s40265-018-1012-5","volume":"78","author":"Markham A.","year":"2018","unstructured":"Markham A.; Duggan S.; Cemiplimab: First global approval. Drugs  2018,78(17),1841-1846","journal-title":"Drugs"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1007\/s12325-021-01638-5","volume":"38","author":"Paccaly A. J.","year":"2021","unstructured":"Paccaly A. J.; Migden M. R.; Papadopoulos K. P.; Yang F.; Davis J. D.; Rippley R. K.; Lowy I.; Fury M. G.; Stankevich E.; Rischin D.; Fixed dose of cemiplimab in patients with advanced malignancies based on population pharmacokinetic analysis. Adv Ther  2021,38(5),2365-2378","journal-title":"Adv Ther"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/CJI.0000000000000476","volume":"46","author":"Huang Y.","year":"2023","unstructured":"Huang Y.; Khan F.; Saraiya N. V.; Punjabi O. S.; Gulati V.; Erickson A. R.; Yeh S.; Vogt-Koyanagi-harada-like syndrome induced by checkpoint inhibitor cemiplimab. J Immunother  2023,46(8),295-298","journal-title":"J Immunother"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1038\/s41591-022-01977-y","volume":"28","author":"Gogishvili M.","year":"2022","unstructured":"Gogishvili M.; Melkadze T.; Makharadze T.; Giorgadze D.; Dvorkin M.; Penkov K.; Laktionov K.; Nemsadze G.; Nechaeva M.; Rozhkova I.; Kalinka E.; Gessner C.; Moreno-Jaime B.; Passalacqua R.; Li S.; McGuire K.; Kaul M.; Paccaly A.; Quek R.G.W.; Gao B.; Seebach F.; Weinreich D.M.; Yancopoulos G.D.; Lowy I.; Gullo G.; Rietschel P.; Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: A randomized, controlled, double-blind phase 3 trial. Nat Med  2022,28(11),2374-2380","journal-title":"Nat Med"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.3390\/biomedicines10123154","volume":"10","author":"Jeong T. J.","year":"2022","unstructured":"Jeong T. J.; Lee H. T.; Gu N.; Jang Y. J.; Choi S. B.; Park U. B.; Lee S. H.; Heo Y. S.; The high-resolution structure reveals remarkable similarity in PD-1 binding of cemiplimab and dostarlimab, the FDA-approved antibodies for cancer immunotherapy.. Biomedicines  2022,10(12),3154","journal-title":"Biomedicines"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"730666","DOI":"10.3389\/fimmu.2021.730666","volume":"12","author":"Zhang L.","year":"2022","unstructured":"Zhang L.; Hao B.; Geng Z.; Geng Q.; Toripalimab: The first domestic anti-tumor PD-1 antibody in China. Front Immunol  2022,12,730666","journal-title":"Front Immunol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ejca.2020.01.028","volume":"130","author":"Yang J.","year":"2020","unstructured":"Yang J.; Dong L.; Yang S.; Han X.; Han Y.; Jiang S.; Yao J.; Zhang Z.; Zhang S.; Liu P.; Qin Y.; Wu H.; Feng H.; Yao S.; Sun Y.; Song H.; Shi Y.; Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study. Eur J Cancer  2020,130,182-192","journal-title":"Eur J Cancer"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"100574","DOI":"10.1016\/j.medj.2025.100574","volume":"6","author":"Zeng L.","year":"2025","unstructured":"Zeng L.; Yan H.; Jiang W.; Qin H.; Dai J.; Zhang Y.; Wei S.; Chen S.; Liu L.; Xiong Y.; Yang H.; Li Y.; Wang Z.; Deng L.; Xu Q.; Peng L.; Zhang R.; Fang C.; Chen X.; Deng J.; Wang J.; Li T.; Liu H.; Zhang G.; Yang N.; Zhang Y.; Toripalimab plus platinum-doublet chemotherapy as perioperative therapy for initially unresectable NSCLC: An open-label, phase 2 trial.. Med  2025,6(6),100574","journal-title":"Med"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1200\/JCO.2021.39.15_suppl.2535","volume":"39","author":"Ren X.","year":"2021","unstructured":"Ren X.; Zhang W.; A single-arm phase Ib study of multiple target cytotoxic T-lymphocyte (MCTL) in combination with toripalimab as second-line therapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol  2021,39(15_suppl),2535-2535","journal-title":"J Clin Oncol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41392-021-00751-9","volume":"6","author":"Jiang T.","year":"2021","unstructured":"Jiang T.; Wang P.; Zhang J.; Zhao Y.; Zhou J.; Fan Y.; Shu Y.; Liu X.; Zhang H.; He J.; Gao G.; Mu X.; Bao Z.; Xu Y.; Guo R.; Wang H.; Deng L.; Ma N.; Zhang Y.; Feng H.; Yao S.; Wu J.; Chen L.; Zhou C.; Ren S.; Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: A multicenter phase-II trial. Signal Transduct Target Ther  2021,6(1),355","journal-title":"Signal Transduct Target Ther"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"S1010","DOI":"10.1016\/j.annonc.2021.08.1912","volume":"32","author":"Jiang M.","year":"2021","unstructured":"Jiang M.; Wang Y.; Zhang X.; 1310P Toripalimab combined with chemotherapy as second-line treatment of advanced non-small cell lung cancer (NSCLC): A single center retrospective study. Ann Oncol  2021,32,S1010","journal-title":"Ann Oncol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"e21053","DOI":"10.1200\/JCO.2021.39.15_suppl.e21053","volume":"39","author":"Zhao J.","year":"2021","unstructured":"Zhao J.; Li J.; Chen H.; Yang X.; Zhong J.; Zhuo M.; Jia B.; An T.; Wu M.; Wang Z.; Ding L.; Mao L.; A phase II study of vorolanib in combination with toripalimab in patients with non-small cell lung cancer. J Clin Oncol  2021,39(15_suppl),e21053-e21053","journal-title":"J Clin Oncol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"743558","DOI":"10.3389\/fpubh.2021.743558","volume":"9","author":"Xiang G.","year":"2021","unstructured":"Xiang G.; Gu L.; Chen X.; Wang F.; Chen B.; Zhao J.; Lu Y.; Chang F.; Zhu Y.; Economic evaluation of first-line camrelizumab for advanced non-small-cell lung cancer in China.. Front Public Health  2021,9,743558","journal-title":"Front Public Health"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"594558","DOI":"10.3389\/fonc.2020.594558","volume":"10","author":"Zhang L.","year":"2020","unstructured":"Zhang L.; Mai W.; Jiang W.; Geng Q.; Sintilimab: A promising anti-Tumor PD-1 antibody.. Front Oncol  2020,10,594558","journal-title":"Front Oncol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"830380","DOI":"10.3389\/fphar.2022.830380","volume":"13","author":"Gong J.","year":"2022","unstructured":"Gong J.; Su D.; Shang J.; Xu S.; Tang L.; Sun Z.; Liu G.; Cost-effectiveness of tislelizumab versus docetaxel for previously treated advanced non-small-cell lung cancer in China.. Front Pharmacol  2022,13,830380","journal-title":"Front Pharmacol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"728440","DOI":"10.3389\/fphar.2021.728440","volume":"12","author":"Qiao L.","year":"2021","unstructured":"Qiao L.; Zhou Z.; Zeng X.; Tan C.; Cost-effectiveness of domestic PD-1 inhibitor camrelizumab combined with chemotherapy in the first-line treatment of advanced nonsquamous non\u2013small-cell lung cancer in China. Front Pharmacol  2021,12,728440","journal-title":"Front Pharmacol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.jtho.2020.07.014","volume":"15","author":"Yang Y.","year":"2020","unstructured":"Yang Y.; Wang Z.; Fang J.; Yu Q.; Han B.; Cang S.; Chen G.; Mei X.; Yang Z.; Ma R.; Bi M.; Ren X.; Zhou J.; Li B.; Song Y.; Feng J.; Li J.; He Z.; Zhou R.; Li W.; Lu Y.; Wang Y.; Wang L.; Yang N.; Zhang Y.; Yu Z.; Zhao Y.; Xie C.; Cheng Y.; Zhou H.; Wang S.; Zhu D.; Zhang W.; Zhang L.; Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic Nonsquamous NSCLC: A randomized, double-blind, phase 3 study (Oncology pRogram by InnovENT anti-PD-1-11). J Thorac Oncol  2020,15(10),1636-1646","journal-title":"J Thorac Oncol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.jtho.2021.07.015","volume":"16","author":"Yang Y.","year":"2021","unstructured":"Yang Y.; Sun J.; Wang Z.; Fang J.; Yu Q.; Han B.; Cang S.; Chen G.; Mei X.; Yang Z.; Ma R.; Bi M.; Ren X.; Zhou J.; Li B.; Song Y.; Feng J.; Li J.; He Z.; Zhou R.; Li W.; Lu Y.; Zhou H.; Wang S.; Sun L.; Puig O.; Mancao C.; Peng B.; Fang W.; Xu W.; Zhang L.; Updated overall survival data and predictive biomarkers of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC in the phase 3 ORIENT-11 study. J Thorac Oncol  2021,16(12),2109-2120","journal-title":"J Thorac Oncol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.jtho.2021.04.011","volume":"16","author":"Zhou C.","year":"2021","unstructured":"Zhou C.; Wu L.; Fan Y.; Wang Z.; Liu L.; Chen G.; Zhang L.; Huang D.; Cang S.; Yang Z.; Zhou J.; Zhou C.; Li B.; Li J.; Fan M.; Cui J.; Li Y.; Zhao H.; Fang J.; Xue J.; Hu C.; Sun P.; Du Y.; Zhou H.; Wang S.; Zhang W.; Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: Results from a randomized, double-blind, phase 3 trial (ORIENT-12). J Thorac Oncol  2021,16(9),1501-1511","journal-title":"J Thorac Oncol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s40265-019-01167-0","volume":"79","author":"Markham A.","year":"2019","unstructured":"Markham A.; Keam S. J.; Camrelizumab: First Global Approval. Drugs  2019,79(12),1355-1361","journal-title":"Drugs"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fphar.2017.00561","volume":"8","author":"Alsaab H.O.","year":"2017","unstructured":"Alsaab H.O.; Sau S.; Alzhrani R.; Tatiparti K.; Bhise K.; Kashaw S.K.; Iyer A.K.; PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations, and clinical outcome. Front Pharmacol  2017,8(AUG),561","journal-title":"Front Pharmacol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"441","DOI":"10.21037\/atm-21-4792","volume":"10","author":"Gao G.","year":"2022","unstructured":"Gao G.; Zhao J.; Ren S.; Wang Y.; Chen G.; Chen J.; Gu K.; Guo R.; Pan Y.; Wang Q.; Li W.; Yang X.; Zhou C.; Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer. Ann Transl Med  2022,10(8),441-441","journal-title":"Ann Transl Med"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s00262-021-03091-3","volume":"71","author":"Yang J.J.","year":"2022","unstructured":"Yang J.J.; Huang C.; Fan Y.; Pan H.; Feng J.; Jiang L.; Li X.Y.; Liu X.Q.; Xiong J.P.; Zhao Y.Q.; Cheng Y.; Ma R.; Wang J.; Wang Y.; Liu Y.H.; Lin D.M.; Wang T.; Shi W.; Zou J.; Wu Y.L.; Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: A phase II study. Cancer Immunol Immunother  2022,71(6),1393-1402","journal-title":"Cancer Immunol Immunother"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"009240","DOI":"10.1136\/jitc-2024-009240","volume":"12","author":"Zhou C.","year":"2024","unstructured":"Zhou C.; Chen G.; Huang Y.; Zhou J.; Lin L.; Feng J.; Wang Z.; Shu Y.; Shi J.; Hu Y.; Wang Q.; Cheng Y.; Wu F.; Chen J.; Lin X.; Wang Y.; Huang J.; Cui J.; Cao L.; Liu Y.; Zhang Y.; Pan Y.; Zhao J.; Wang L.; Chang J.; Chen Q.; Ren X.; Zhang W.; Fan Y.; He Z.; Fang J.; Gu K.; Dong X.; Jin F.; Gao H.; An G.; Ding C.; Jiang X.; Xiong J.; Zhou X.; Hu S.; Lu P.; Liu A.; Guo S.; Huang J.; Zhu C.; Zhao J.; Gao B.; Chen Y.; Hu C.; Zhang J.; Zhang H.; Zhao H.; Wang Z.; Ma X.; Shi W.; Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study.. J Immunother Cancer  2024,12(11),009240","journal-title":"J Immunother Cancer"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"786","DOI":"10.21037\/tlcr-23-121","volume":"12","author":"Wang R.","year":"2023","unstructured":"Wang R.; Shi M.; Ji M.; Han Z.; Chen L.; Liu Y.; Lu K.; Liu L.; Chen B.; Zhang X.; Miao L.; Shu Y.; Real world experience with camrelizumab in patients with advanced non-small cell lung cancer: A prospective multicenter cohort study (NOAH-LC-101). Transl Lung Cancer Res  2023,12(4),786-796","journal-title":"Transl Lung Cancer Res"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1494708","DOI":"10.3389\/fimmu.2025.1494708","volume":"16","author":"Zhao D.","year":"2025","unstructured":"Zhao D.; Bi M.; Cheng X.; Wang S.; Cheng H.; Xia X.; Chen H.; Zhang Y.; Hu Z.; Cao Q.; Liang H.; Wang F.; Min X.; Xu L.; Feng K.; Zhou J.; Li X.; Wang R.; Xie H.; Chen X.; Gu K.; Camrelizumab-based therapies for the treatment of advanced lung cancer: A prospective, open-label, multicenter, observational, real-world study. Front Immunol  2025,16,1494708","journal-title":"Front Immunol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1080\/13543784.2020.1833857","volume":"29","author":"Liu S. Y.","year":"2020","unstructured":"Liu S. Y.; Wu Y. L.; Tislelizumab: An investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). Expert Opin Investig Drugs  2020,29(12),1355-1364","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"103727","DOI":"10.1016\/j.esmoop.2024.103727","volume":"9","author":"Wang J.","year":"2024","unstructured":"Wang J.; Lu S.; Yu X.; Hu Y.; Zhao J.; Sun M.; Yu Y.; Hu C.; Yang K.; Song Y.; Lin X.; Liang L.; Leaw S.; Zheng W.; Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: Final analysis of the randomized, phase III RATIONALE-307 trial. ESMO Open  2024,9(10),103727","journal-title":"ESMO Open"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.lungcan.2020.06.007","volume":"147","author":"Wang Z.","year":"2020","unstructured":"Wang Z.; Zhao J.; Ma Z.; Cui J.; Shu Y.; Liu Z.; Cheng Y.; Leaw S. J.; Wu Y.; Ma Y.; Tan W.; Ma X.; Zhang Y.; Wang J.; A phase 2 study of tislelizumab in combination with platinum-based chemotherapy as first-line treatment for advanced lung cancer in Chinese patients. Lung Cancer  2020,147,259-268","journal-title":"Lung Cancer"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"498","DOI":"10.21037\/jtd-23-1103","volume":"16","author":"Chen H.","year":"2024","unstructured":"Chen H.; Zhang J.; Chen C.; Zheng W.; Zheng B.; Efficacy and safety of neoadjuvant tislelizumab combined with chemotherapy in locally advanced non-small cell lung cancer\u2014A retrospective cohort study. J Thorac Dis  2024,16(1),498-506","journal-title":"J Thorac Dis"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"S126","DOI":"10.1016\/j.jtho.2024.09.227","volume":"19","author":"Chen X.","year":"2024","unstructured":"Chen X.; Zhang H.; Li W.; Qu Y.; Qu X.; Zhou R.; Hong H.; Zhu Y.; Chai X.; Liu L.; Li Y.; MA17.09 Efficacy and safety of tislelizumab plus anlotinib and 2-cycle irinotecan as second-line treatment for ES-small cell lung cancer (ESTAIL).. J Thorac Oncol  2024,19(10),S126-S127","journal-title":"J Thorac Oncol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"100557","DOI":"10.1016\/j.iotech.2023.100557","volume":"20","author":"Fan Y.","year":"2023","unstructured":"Fan Y.; Li H.; Chen K.; Gong L.; Huang Z.; Xu Y.; Yu X.; Lou G.; Lu H.; Hong W.; Zhao J.; Wang W.; Gu C.; Xie F.; Xu X.; Han N.; 85P Phase II trial of tislelizumab plus sitravatinib as maintenance therapy in extensive-stage small-cell lung cancer (ES-SCLC). Immuno-Oncol Technol  2023,20,100557","journal-title":"Immuno-Oncol Technol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/s12672-024-01278-5","volume":"15","author":"Huang X.","year":"2024","unstructured":"Huang X.; Zhu L.; Liu J.; Wang Y.; Wang Y.; Xia P.; Lv W.; Hu J.; Tislelizumab synergizes with surgery to augment the survival benefit in stage II-III non-small cell lung cancer. Discover Oncology  2024,15(1),390","journal-title":"Discover Oncology"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1080\/14737140.2018.1483241","volume":"18","author":"Redman J. M.","year":"2018","unstructured":"Redman J. M.; Madan R. A.; Spotlight on atezolizumab and its potential as an oncology agent.. Expert Rev Anticancer Ther  2018,18(8),719-722","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"S3155","DOI":"10.21037\/jtd.2018.07.92","volume":"10","author":"Akamine T.","year":"2018","unstructured":"Akamine T.; Toyokawa G.; Tagawa T.; Seto T.; Atezolizumab in non-squamous non-small cell lung cancer. J Thorac Dis  2018,10(S26),S3155-S3159","journal-title":"J Thorac Dis"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"1175960","DOI":"10.3389\/fimmu.2023.1175960","volume":"14","author":"Liu C.","year":"2023","unstructured":"Liu C.; Zeng L.; Deng C.; Jiang W.; Wang Y.; Zhou Y.; Liu L.; Wang S.; Zhou C.; Qiu Z.; Zeng F.; Wu F.; Weng J.; Liu X.; Yang N.; Ma F.; Hypofractionated radiotherapy with immunochemotherapy for extensive-stage small-cell lung cancer. Front Immunol  2023,14,1175960","journal-title":"Front Immunol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2147\/DDDT.S141491","volume":"12","author":"Faiena I.","year":"2018","unstructured":"Faiena I.; Cummings A.L.; Crosetti A.M.; Pantuck A.J.; Chamie K.; Drakaki A.; Durvalumab: An investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.. Drug Des Devel Ther  2018,12,209-215","journal-title":"Drug Des Devel Ther"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s11523-021-00843-0","volume":"16","author":"Al-Salama Z.T.","year":"2021","unstructured":"Al-Salama Z.T.; Durvalumab: A review in extensive-stage SCLC. Target Oncol  2021,16(6),857-864","journal-title":"Target Oncol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"Antonia S. J.","year":"2018","unstructured":"Antonia S. J.; Villegas A.; Daniel D.; Vicente D.; Murakami S.; Hui R.; Kurata T.; Chiappori A.; Lee K. H.; de Wit M.; Cho B. C.; Bourhaba M.; Quantin X.; Tokito T.; Mekhail T.; Planchard D.; Kim Y. C.; Karapetis C. S.; Hiret S.; Ostoros G.; Kubota K.; Gray J. E.; Paz-Ares L.; de Castro Carpe\u00f1o J.; Faivre-Finn C.; Reck M.; Vansteenkiste J.; Spigel D. R.; Wadsworth C.; Melillo G.; Taboada M.; Dennis P. A.; \u00d6zg\u00fcro\u011flu M.; Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med  2018,379(24),2342-2350","journal-title":"N Engl J Med"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"1753466619885530","DOI":"10.1177\/1753466619885530","volume":"13","author":"Botticella A.","year":"2019","unstructured":"Botticella A.; Mezquita L.; Le Pechoux C.; Planchard D.; Durvalumab for stage III non-small-cell lung cancer patients: Clinical evidence and real-world experience.. Ther Adv Respir Dis  2019,13,1753466619885530","journal-title":"Ther Adv Respir Dis"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1016\/j.jtho.2022.11.002","volume":"18","author":"Zhao B.","year":"2023","unstructured":"Zhao B.; Li H.; Ma W.; Durvalumab after chemoradiotherapy for patients with unresectable stage III NSCLC: The PACIFIC-R study. J Thorac Oncol  2023,18(4),e38-e39","journal-title":"J Thorac Oncol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"100408","DOI":"10.1016\/j.esmoop.2022.100408","volume":"7","author":"Paz-Ares L.","year":"2022","unstructured":"Paz-Ares L.; Chen Y.; Reinmuth N.; Hotta K.; Trukhin D.; Statsenko G.; Hochmair M. J.; \u00d6zg\u00fcro\u011flu M.; Ji J. H.; Garassino M. C.; Voitko O.; Poltoratskiy A.; Musso E.; Havel L.; Bondarenko I.; Losonczy G.; Conev N.; Mann H.; Dalvi T. B.; Jiang H.; Goldman J. W.; Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open  2022,7(2),100408","journal-title":"ESMO Open"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1038\/s41467-023-38611-5","volume":"14","author":"Capdevila J.","year":"2023","unstructured":"Capdevila J.; Hernando J.; Teule A.; Lopez C.; Garcia-Carbonero R.; Benavent M.; Custodio A.; Garcia-Alvarez A.; Cubillo A.; Alonso V.; Carmona-Bayonas A.; Alonso-Gordoa T.; Crespo G.; Jimenez-Fonseca P.; Blanco M.; Viudez A.; La Casta A.; Sevilla I.; Segura A.; Llanos M.; Landolfi S.; Nuciforo P.; Manzano J. L.; Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin. Nat Commun  2023,14(1),2973","journal-title":"Nat Commun"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11523-018-0571-4","volume":"13","author":"Shirley M.","year":"2018","unstructured":"Shirley M.; Avelumab: A review in metastatic merkel cell carcinoma. Target Oncol  2018,13(3),409-416","journal-title":"Target Oncol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1080\/17512433.2018.1445966","volume":"11","author":"Gaiser M. R.","year":"2018","unstructured":"Gaiser M. R.; Bongiorno M.; Brownell I.; PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma. Expert Rev Clin Pharmacol  2018,11(4),345-359","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=118","first-page":"31","volume":"5","author":"Neumann M.","year":"2022","unstructured":"Neumann M.; Murphy N.; Seetharamu N.; The evolving role of PD-L1 inhibition in non-small cell lung cancer: A review of durvalumab and avelumab. Cancer Med J  2022,5(1),31-45","journal-title":"Cancer Med J"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jtho.2023.09.1445","volume":"19","author":"Reck M.","year":"2024","unstructured":"Reck M.; Barlesi F.; Yang J. C. H.; Westeel V.; Felip E.; \u00d6zg\u00fcro\u011flu M.; Dols M. C.; Sullivan R.; Kowalski D. M.; Andric Z.; Lee D. H.; Sezer A.; Hu P.; Wang X.; von Heydebreck A.; Jacob N.; Mehr K. T.; Park K.; Avelumab versus platinum-based doublet chemotherapy as first-line treatment for patients with high-expression programmed death-ligand 1\u2013Positive Metastatic NSCLC: Primary analysis from the phase 3 JAVELIN lung 100 trial. J Thorac Oncol  2024,19(2),297-313","journal-title":"J Thorac Oncol"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"100685","DOI":"10.1016\/j.jtocrr.2024.100685","volume":"5","author":"Solomon B.J.","year":"2024","unstructured":"Solomon B.J.; Dagogo-Jack I.; Lee S.H.; Boyer M.J.; Ramalingam S.S.; Carcereny E.; Felip E.; Han J.Y.; Hida T.; Hughes B.G.M.; Kim S.W.; Nishio M.; Seto T.; Okamoto T.; Zhang X.; Martini J.F.; Wang E.; De Beukelaer S.; Bauer T.M.; Avelumab in combination with lorlatinib or crizotinib in patients with previously treated advanced NSCLC: Phase 1b\/2 results from the JAVELIN lung 101 trial. JTO Clinical and Research Reports  2024,5(7),100685","journal-title":"JTO Clinical and Research Reports"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"S2451","DOI":"10.21037\/jtd.2018.04.52","volume":"10","author":"Sebastian N. T.","year":"2018","unstructured":"Sebastian N. T.; Xu-Welliver M.; Williams T. M.; Stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC): Contemporary insights and advances.. J Thorac Dis  (Suppl. 21)2018,10(S21),S2451-S2464","journal-title":"J Thorac Dis"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"v648","DOI":"10.1093\/annonc\/mdz260.096","volume":"30","author":"Solomon B.","year":"2019","unstructured":"Solomon B.; Callejo A.; Bar J.; Berchem G.; Bazhenova L.; Saintigny P.; Raymond E.; Girard N.; Sulaiman R.; Bresson C.; Wunder F.; Lee J.J.; Raynaud J.; Rubin E.; Young B.; Lazar V.; Felip E.; Onn A.; Leyland-Jones B.; Kurzrock R.; Survival prolongation by rationale innovative genomics (SPRING): An international WIN consortium phase I study exploring safety and efficacy of avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer (NSCLC) with integrated genomic and transcriptomic correlates. Ann Oncol  2019,30,v648","journal-title":"Ann Oncol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.2217\/fon-2021-0930","volume":"18","author":"Hrinczenko B.","year":"2022","unstructured":"Hrinczenko B.; Iannotti N.; Goel S.; Spigel D.; Safran H.; Taylor M. H.; Bennouna J.; Wong D. J.; Kelly K.; Verschraegen C.; Bajars M.; Manitz J.; Ruisi M.; Gulley J. L.; Long-term avelumab in advanced non-small-cell lung cancer: Summaries and post hoc analyses from JAVELIN Solid Tumor. Future Oncol  2022,18(11),1333-1342","journal-title":"Future Oncol"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"001064","DOI":"10.1136\/jitc-2020-001064","volume":"8","author":"Verschraegen C.F.","year":"2020","unstructured":"Verschraegen C.F.; Jerusalem G.; McClay E.F.; Iannotti N.; Redfern C.H.; Bennouna J.; Chen F.L.; Kelly K.; Mehnert J.; Morris J.C.; Taylor M.; Spigel D.; Wang D.; Grote H.J.; Zhou D.; Munshi N.; Bajars M.; Gulley J.L.; Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: Results from a phase Ib cohort of the JAVELIN Solid Tumor study. J Immunother Cancer  2020,8(2),001064","journal-title":"J Immunother Cancer"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1177\/1060028018768809","volume":"52","author":"Joseph J.","year":"2018","unstructured":"Joseph J.; Zobniw C.; Davis J.; Anderson J.; Trinh V. A.; Avelumab: A review of its application in metastatic merkel cell carcinoma. Ann Pharmacother  2018,52(9),928-935","journal-title":"Ann Pharmacother"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s10637-022-01287-7","volume":"40","author":"Shimizu T.","year":"2022","unstructured":"Shimizu T.; Nakajima T.E.; Yamamoto N.; Yonemori K.; Koyama T.; Kondo S.; Sunakawa Y.; Izawa N.; Horie Y.; Xiang S.; Xu S.; Qin L.; Gong J.; Liu D.; Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors.. Invest New Drugs  2022,40(5),1021-1031","journal-title":"Invest New Drugs"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"1437260","DOI":"10.3389\/fonc.2024.1437260","volume":"14","author":"Wu S.","year":"2024","unstructured":"Wu S.; Dong C.; Hu C.; Hui K.; Jiang X.; Case report: Combination therapy of envafolimab with endostar for advanced non-small cell lung cancer with low PD-L1 expression. Front Oncol  2024,14,1437260","journal-title":"Front Oncol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"e1514","DOI":"10.1002\/onco.13817","volume":"26","author":"Papadopoulos K. P.","year":"2021","unstructured":"Papadopoulos K. P.; Harb W.; Peer C. J.; Hua Q.; Xu S.; Lu H.; Lu N.; He Y.; Xu T.; Dong R.; Gong J.; Liu D.; First-in-human phase I study of envafolimab, a novel subcutaneous single-domain Anti-PD-L1 antibody, in patients with advanced solid tumors. Oncologist  2021,26(9),e1514-e1525","journal-title":"Oncologist"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13045-021-01095-1","volume":"14","author":"Li J.","year":"2021","unstructured":"Li J.; Deng Y.; Zhang W.; Zhou A.P.; Guo W.; Yang J.; Yuan Y.; Zhu L.; Qin S.; Xiang S.; Lu H.; Gong J.; Xu T.; Liu D.; Shen L.; Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair\/microsatellite instability high solid tumors. J Hematol Oncol  2021,14(1),95","journal-title":"J Hematol Oncol"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"7175","DOI":"10.1002\/cam4.7175","volume":"13","author":"Zhang Y.","year":"2024","unstructured":"Zhang Y.; Chen Z.; Liu Y.; Han L.; Jiang W.; Wang Q.; Shi J.; Lu L.; Li J.; Zhang M.; Huang Y.; Yang Y.; Hou X.; Zhang L.; Li J.; Fang W.; Chen G.; Chidamide plus envafolimab as subsequent treatment in advanced non\u2010small cell lung cancer patients resistant to anti\u2010PD\u20101 therapy: A multicohort, open\u2010label, phase II trial with biomarker analysis.. Cancer Med  2024,13(7),7175","journal-title":"Cancer Med"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"1368059","DOI":"10.3389\/fonc.2024.1368059","volume":"14","author":"Dong C.","year":"2024","unstructured":"Dong C.; Hu C.; Jiang Y.; Hui K.; Jiang X.; Case report: Envafolimab combined with Endostar in the treatment of advanced non-small cell lung cancer with malignant pleural effusion. Front Oncol  2024,14,1368059","journal-title":"Front Oncol"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12865-024-00651-x","volume":"25","author":"Geng Q.","year":"2024","unstructured":"Geng Q.; Lu Y.; Li D.; Qin L.; Qi C.; Pu X.; Zhuang Y.; Zhu Y.; Zha Q.; Wang G.; Jiang H.; \u03b2-glucan combined with Envafolimab and Endostar as immune rechallenge for metastatic non-small cell lung cancer. BMC Immunol  2024,25(1),60","journal-title":"BMC Immunol"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"1860476","DOI":"10.1080\/19420862.2020.1860476","volume":"13","author":"Kaplon H.","year":"2021","unstructured":"Kaplon H.; Reichert J.M.; Antibodies to watch in 2021. MAbs  2021,13(1),1860476","journal-title":"MAbs"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"2153410","DOI":"10.1080\/19420862.2022.2153410","volume":"15","author":"Kaplon H.","year":"2023","unstructured":"Kaplon H.; Crescioli S.; Chenoweth A.; Visweswaraiah J.; Reichert J.M.; Antibodies to watch in 2023. MAbs  2023,15(1),2153410","journal-title":"MAbs"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s40265-025-02164-2","volume":"85","author":"Lee A.","year":"2025","unstructured":"Lee A.; Cosibelimab: First approval. Drugs  2025,85(5),695-698","journal-title":"Drugs"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1136\/jitc-2020-SITC2020.0399","volume":"8","author":"Harris D.","year":"2020","unstructured":"Harris D.; Brungs D.; Ladwah R.; Mant A.; McGrath M.; Tazbirkova A.; 399 Cosibelimab, an anti-PD-L1 antibody: Preliminary safety and efficacy results from a global, multicohort phase 1 clinical trial. J Immunother Cancer  2020,8(3),2422-243","journal-title":"J Immunother Cancer"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1097\/COC.0000000000000059","volume":"38","author":"Langer C. J.","year":"2015","unstructured":"Langer C. J.; Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): The role of immune checkpoint inhibitors. Am J Clin Oncol  2015,38(4),422-430","journal-title":"Am J Clin Oncol"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"7474","DOI":"10.1158\/1078-0432.CCR-17-2005","volume":"23","author":"Yi J. S.","year":"2017","unstructured":"Yi J. S.; Ready N.; Healy P.; Dumbauld C.; Osborne R.; Berry M.; Shoemaker D.; Clarke J.; Crawford J.; Tong B.; Harpole D.; D\u2019Amico T. A.; McSherry F.; Dunphy F.; McCall S. J.; Christensen J. D.; Wang X.; Weinhold K. J.; Immune activation in early-stage non\u2013small cell lung cancer patients receiving neoadjuvant chemotherapy plus ipilimumab. Clin Cancer Res  2017,23(24),7474-7482","journal-title":"Clin Cancer Res"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s10555-021-09976-0","volume":"40","author":"Wojtukiewicz M.Z.","year":"2021","unstructured":"Wojtukiewicz M.Z.; Rek M.M.; Karpowicz K.; G\u00f3rska M.; Polity\u0144ska B.; Wojtukiewicz A.M.; Moniuszko M.; Radziwon P.; Tucker S.C.; Honn K.V.; Inhibitors of immune checkpoints\u2014PD-1, PD-L1, CTLA-4\u2014new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer Metastasis Rev  2021,40(3),949-982","journal-title":"Cancer Metastasis Rev"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/annonc\/mds213","volume":"24","author":"Reck M.","year":"2013","unstructured":"Reck M.; Bondarenko I.; Luft A.; Serwatowski P.; Barlesi F.; Chacko R.; Sebastian M.; Lu H.; Cuillerot J.M.; Lynch T.J.; Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase 2 trial.. Ann Oncol  2013,24(1),75-83","journal-title":"Ann Oncol"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1200\/JCO.2016.67.6601","volume":"34","author":"Reck M.","year":"2016","unstructured":"Reck M.; Luft A.; Szczesna A.; Havel L.; Kim S.W.; Akerley W.; Pietanza M.C.; Wu Y.; Zielinski C.; Thomas M.; Felip E.; Gold K.; Horn L.; Aerts J.; Nakagawa K.; Lorigan P.; Pieters A.; Kong Sanchez T.; Fairchild J.; Spigel D.; Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol  2016,34(31),3740-3748","journal-title":"J Clin Oncol"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1200\/JCO.2016.69.0040","volume":"34","author":"Riess J. W.","year":"2016","unstructured":"Riess J. W.; Lara P. N.; Gandara D. R.; Theory meets practice for immune checkpoint blockade in small-cell lung cancer.. J Clin Oncol  2016,34(31),3717-3718","journal-title":"J Clin Oncol"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.3390\/ijms21124427","volume":"21","author":"Kooshkaki O.","year":"2020","unstructured":"Kooshkaki O.; Derakhshani A.; Hosseinkhani N.; Torabi M.; Safaei S.; Brunetti O.; Racanelli V.; Silvestris N.; Baradaran B.; Combination of ipilimumab and nivolumab in cancers: From clinical practice to ongoing clinical trials.. Int J Mol Sci  2020,21(12),4427","journal-title":"Int J Mol Sci"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40265-022-01827-8","volume":"83","author":"Keam S. J.","year":"2023","unstructured":"Keam S. J.; Tremelimumab: First approval. Drugs  2023,83(1),93-102","journal-title":"Drugs"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.1007\/s12325-021-01796-6","volume":"38","author":"Arru C.","year":"2021","unstructured":"Arru C.; De Miglio M. R.; Cossu A.; Muroni M. R.; Carru C.; Zinellu A.; Paliogiannis P.; Durvalumab plus tremelimumab in solid tumors: A systematic review. Adv Ther  2021,38(7),3674-3693","journal-title":"Adv Ther"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1200\/JCO.22.00975","volume":"41","author":"Johnson M. L.","year":"2023","unstructured":"Johnson M. L.; Cho B. C.; Luft A.; Alatorre-Alexander J.; Geater S. L.; Laktionov K.; Kim S. W.; Ursol G.; Hussein M.; Lim F. L.; Yang C. T.; Araujo L. H.; Saito H.; Reinmuth N.; Shi X.; Poole L.; Peters S.; Garon E. B.; Mok T.; Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non\u2013small-cell lung cancer: The phase III POSEIDON study. J Clin Oncol  2023,41(6),1213-1227","journal-title":"J Clin Oncol"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1200\/jco.2015.33.15_suppl.3014","volume":"33","author":"Antonia S.J.","year":"2015","unstructured":"Antonia S.J.; Goldberg S.B.; Balmanoukian A.S.; Sanborn R.E.; Steele K.; Narwal R.; Robbins P.B.; Gu Y.; Karakunnel J.J.; Rizvi N.A.; Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC. J Clin Oncol  2015,33(15_suppl),3014-3014","journal-title":"J Clin Oncol"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.1111\/1759-7714.13684","volume":"11","author":"Kim M.","year":"2020","unstructured":"Kim M.; Keam B.; Ock C.Y.; Kim S.H.; Kim Y.J.; Lim S.M.; Kim J.S.; Kim T.M.; Hong S.H.; Ahn M.S.; Shin S.H.; Kang E.J.; Kim D.W.; Im S.W.; Kim J.I.; Lee J.S.; Kim J.H.; Heo D.S.; Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG\u2010LU16 \u201007. Thorac Cancer  2020,11(12),3482-3489","journal-title":"Thorac Cancer"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"001302","DOI":"10.1136\/jitc-2020-001302","volume":"8","author":"Pakkala S.","year":"2020","unstructured":"Pakkala S.; Higgins K.; Chen Z.; Sica G.; Steuer C.; Zhang C.; Zhang G.; Wang S.; Hossain M. S.; Nazha B.; Beardslee T.; Khuri F. R.; Curran W.; Lonial S.; Waller E. K.; Ramalingam S.; Owonikoko T. K.; Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: A randomized phase II study. J Immunother Cancer  2020,8(2),001302","journal-title":"J Immunother Cancer"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"011140","DOI":"10.1136\/jitc-2024-011140","volume":"13","author":"Morgan C.","year":"2025","unstructured":"Morgan C.; Kurland J.; Patel M.; O'Brien C.; Concepcion P.; Doherty G.J.; Hois S.; Negro A.; Pavlovic D.; Robbins K.A.; Differential safety profiles of durvalumab monotherapy and durvalumab in combination with tremelimumab in adult patients with advanced cancers. J Immunother Cancer  2025,13(5),011140","journal-title":"J Immunother Cancer"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1126\/science.132.3441.1770","volume":"132","author":"Nisonoff A.","year":"1960","unstructured":"Nisonoff A.; Wissler F.C.; Lipman L.N.; Properties of the major component of a peptic digest of rabbit antibody. Science  1960,132,1770-1771","journal-title":"Science"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"2180794","DOI":"10.1080\/19420862.2023.2180794","volume":"15","author":"Pang X.","year":"2023","unstructured":"Pang X.; Huang Z.; Zhong T.; Zhang P.; Wang Z. M.; Xia M.; Li B.; Cadonilimab, a tetravalent PD-1\/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity. MAbs  2023,15(1),2180794","journal-title":"MAbs"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41416-023-02519-0","volume":"130","author":"Chen B.","year":"2024","unstructured":"Chen B.; Yao W.; Li X.; Lin G.; Chu Q.; Liu H.; Du Y.; Lin J.; Duan H.; Wang H.; Xiao Z.; Sun H.; Liu L.; Xu L.; Xu Y.; Xu F.; Kong Y.; Pu X.; Li K.; Wang Q.; Li J.; Li B.; Xia Y.; Wu L.; A phase Ib\/II study of cadonilimab (PD-1\/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer.. Br J Cancer  2024,130(3),450-456","journal-title":"Br J Cancer"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"A313","DOI":"10.1136\/jitc-2021-SITC2021.289","volume":"9","author":"Huang Z.","year":"2021","unstructured":"Huang Z.; Pang X.; Zhong T.; Chen N.; He X.; Xia D.; Jin X.; Wang Z.; Xia X.; Li B.; 289 Cadonilimab, an anti-PD1\/CTLA4 bi-specific antibody with Fc effector null backbone. J Immunother Cancer  (Suppl. 2)2021,9(2),A313-A314","journal-title":"J Immunother Cancer"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"107355","DOI":"10.1016\/j.lungcan.2023.107355","volume":"184","author":"Zhao Y.","year":"2023","unstructured":"Zhao Y.; Ma Y.; Fan Y.; Zhou J.; Yang N.; Yu Q.; Zhuang W.; Song W.; Wang Z.M.; Li B.; Xia Y.; Zhao H.; Zhang L.; A multicenter, open-label phase Ib\/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non\u2013small-cell lung cancer (AK104-202 study).. Lung Cancer  2023,184,107355","journal-title":"Lung Cancer"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"15330338241249690","DOI":"10.1177\/15330338241249690","volume":"23","author":"Chen C.","year":"2024","unstructured":"Chen C.; Chen M.; Bai Y.; Li Y.; Peng J.; Yao B.; Feng J.; Zhou J. G.; Ma H.; A single-arm multi-center phase II clinical trial of Cadonilimab (anti-PD-1\/CTLA-4) in combination with or without conventional second-line treatment for patients with extensive stage small cell lung cancer.. Technol Cancer Res Treat  2024,23,15330338241249690","journal-title":"Technol Cancer Res Treat"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/s41467-024-45160-y","volume":"15","author":"Li Q.","year":"2024","unstructured":"Li Q.; Liu J.; Zhang Q.; Ouyang Q.; Zhang Y.; Liu Q.; Sun T.; Ye F.; Zhang B.; Xia S.; Zhang B.; Xu B.; The anti-PD-L1\/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: A multicenter phase II trial.. Nat Commun  2024,15(1),1015","journal-title":"Nat Commun"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"006654","DOI":"10.1136\/jitc-2022-006654","volume":"11","author":"Ma Y.","year":"2023","unstructured":"Ma Y.; Xue J.; Zhao Y.; Zhang Y.; Huang Y.; Yang Y.; Fang W.; Guo Y.; Li Q.; Ge X.; Sun J.; Zhang B.; Zhang Y.; Xiao J.; Zhang L.; Zhao H.; Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors. J Immunother Cancer  2023,11(6),006654","journal-title":"J Immunother Cancer"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"112936","DOI":"10.1016\/j.ejca.2023.05.024","volume":"190","author":"Xiong A.","year":"2023","unstructured":"Xiong A.; Li W.; Li X.; Fan Y.; Ma Z.; Fang J.; Xie Q.; Zhuang W.; Kang M.; Wang J.; Xu T.; Xu M.; Zhi L.; Liu Q.; Wang N.; Zhou C.; Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: A phase II study. Eur J Cancer  2023,190,112936","journal-title":"Eur J Cancer"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"101470","DOI":"10.1016\/j.xcrm.2024.101470","volume":"5","author":"Zhao Y.","year":"2024","unstructured":"Zhao Y.; Chen G.; Li X.; Wu J.; Chang B.; Hu S.; Yang S.; Xu T.; Liu Y.; Wang N.; Zhang L.; Huang Y.; KN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment for metastatic NSCLC: A multicenter phase 2 trial. Cell Rep Med  2024,5(3),101470","journal-title":"Cell Rep Med"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"100163","DOI":"10.1016\/j.xcrm.2020.100163","volume":"1","author":"Berezhnoy A.","year":"2020","unstructured":"Berezhnoy A.; Sumrow B.J.; Stahl K.; Shah K.; Liu D.; Li J.; Hao S.S.; De Costa A.; Kaul S.; Bendell J.; Cote G.M.; Luke J.J.; Sanborn R.E.; Sharma M.R.; Chen F.; Li H.; Diedrich G.; Bonvini E.; Moore P.A.; Development and preliminary clinical activity of PD-1-guided CTLA-4 blocking bispecific DART molecule.. Cell Rep Med  2020,1(9),100163","journal-title":"Cell Rep Med"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"67","DOI":"10.21622\/AMPDR.2025.05.1.1222","volume":"5","author":"Ansah E. O.","year":"2025","unstructured":"Ansah E. O.; Ansong B.; Kyei F.; Current advances in bispecific T cell\u2013engaging therapies. Adv Med Pharm Dent Res  2025,5(1),67-81","journal-title":"Adv Med Pharm Dent Res"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"S704","DOI":"10.1016\/j.annonc.2020.08.1140","volume":"31","author":"Sharma M.","year":"2020","unstructured":"Sharma M.; Sanborn R. E.; Cote G. M.; Bendell J. C.; Kaul S.; Chen F.; Berezhnoy A.; Moore P.; Bonvini E.; Sumrow B. J.; Luke J. J.; 1020O A phase I, first-in-human, open-label, dose escalation study of MGD019, an investigational bispecific PD-1 x CTLA-4 DART\u00ae molecule in patients with advanced solid tumours. Ann Oncol  2020,31,S704-S705","journal-title":"Ann Oncol"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"880","DOI":"10.3390\/cancers17050880","volume":"17","author":"Almawash S.","year":"2025","unstructured":"Almawash S.; Revolutionary cancer therapy for personalization and improved efficacy: Strategies to overcome resistance to immune checkpoint inhibitor therapy. Cancers  2025,17(5),880","journal-title":"Cancers"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.3390\/ijms23063087","volume":"23","author":"Kr\u017cy\u017canowska N.","year":"2022","unstructured":"Kr\u017cy\u017canowska N.; Wojas-Krawczyk K.; Milanowski J.; Krawczyk P.; Future prospects of immunotherapy in non-small-cell lung cancer patients: Is there hope in other immune checkpoints targeting molecules?. Int J Mol Sci  2022,23(6),3087","journal-title":"Int J Mol Sci"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"1155778","DOI":"10.3389\/fimmu.2023.1155778","volume":"14","author":"Farhangnia P.","year":"2023","unstructured":"Farhangnia P.; Ghomi S. M.; Akbarpour M.; Delbandi A. A.; Bispecific antibodies targeting CTLA-4: Game-changer troopers in cancer immunotherapy. Front Immunol  2023,14,1155778","journal-title":"Front Immunol"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41392-021-00868-x","volume":"7","author":"Jin S.","year":"2022","unstructured":"Jin S.; Sun Y.; Liang X.; Gu X.; Ning J.; Xu Y.; Chen S.; Pan L.; Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduct Target Ther  2022,7(1),39","journal-title":"Signal Transduct Target Ther"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.3390\/cancers14174278","volume":"14","author":"Belli C.","year":"2022","unstructured":"Belli C.; Antonarelli G.; Repetto M.; Boscolo Bielo L.; Crimini E.; Curigliano G.; Targeting cellular components of the tumor microenvironment in solid malignancies. Cancers  2022,14(17),4278","journal-title":"Cancers"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1136\/jitc-2022-SITC2022.0521","volume":"10","author":"Zhong T.","year":"2022","unstructured":"Zhong T.; 521 AK112, a tetravalent bispecific antibody targeting PD-1 and VEGF, enhances binding avidity and functional activities and elicits potent anti-tumor efficacy in pre-clinical studies. J Immunother Cancer  2022,10(2),546-547","journal-title":"J Immunother Cancer"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"9087","DOI":"10.1200\/JCO.2023.41.16_suppl.9087","volume":"41","author":"Zhang L.","year":"2023","unstructured":"Zhang L.; Fang W.; Zhao Y.; Yang Y.; Zhou N.; Chen L.; Huang Y.; Chen J.; Zhuang L.; Du Y.; Zhuang W.; Yu Q.; Zhao Y.; Zhou M.; Zhang W.; Zhang Y.; Wan Y.; Song W.; Xia Y.; Phase II results of ivonescimab (AK112\/ SMT112), a novel PD-1\/VEGF bispecific, in combination with chemotherapy for first line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA) in EGFR\/ALK. J Clin Oncol  2023,41(16_suppl),9087-9087","journal-title":"J Clin Oncol"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/CM9.0000000000002460","volume":"136","author":"Wang W.","year":"2023","unstructured":"Wang W.; Qiu T.; Li F.; Ren S.; Current status and future perspectives of bispecific antibodies in the treatment of lung cancer. Chin Med J  2023,136(4),379-393","journal-title":"Chin Med J"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.2022.40.16_suppl.9040","volume":"1","author":"Zhou C.","year":"2022","unstructured":"Zhou C.; Ren S.; Luo Y.; Wang L.; Xiong A.; Su C.; Zhang Z.; A phase Ib\/II study of AK112, a PD-1\/VEGF bispecific antibody, as first or second-line therapy for advanced non-small cell lung cancer (NSCLC). Hypertension  2022,1,1","journal-title":"Hypertension"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.3390\/ph16101461","volume":"16","author":"Khosla A. A.","year":"2023","unstructured":"Khosla A. A.; Jatwani K.; Singh R.; Reddy A.; Jaiyesimi I.; Desai A.; Bispecific antibodies in lung cancer: A state-of-the-art review. Pharmaceuticals  2023,16(10),1461","journal-title":"Pharmaceuticals"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"778978","DOI":"10.3389\/fimmu.2021.778978","volume":"12","author":"Cui X.","year":"2021","unstructured":"Cui X.; Jia H.; Xin H.; Zhang L.; Chen S.; Xia S.; Li X.; Xu W.; Chen X.; Feng Y.; Wei X.; Yu H.; Wang Y.; Zhan Y.; Zhu X.; Zhang X.; A novel bispecific antibody targeting PD-L1 and VEGF with combined anti-tumor activities. Front Immunol  2021,12,778978","journal-title":"Front Immunol"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1200\/JCO.2023.41.16_suppl.2536","volume":"41","author":"Guo Y.","year":"2023","unstructured":"Guo Y.; Guo J.; Cheng Y.; Wang Z.; Li Y.; Lv D.; Yin Y.; Li G.; Wu L.; Huang Y.; Wei S.; Shen L.; Duan H.; Cui J.; Luo H.; Li X.; Nan K.; Wang C.; Luo S.; Liu R.; Phase Ib\/IIa safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced solid tumors. J Clin Oncol  2023,41(16_suppl),2536-2536","journal-title":"J Clin Oncol"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jtho.2016.10.014","volume":"12","author":"Drilon A.","year":"2017","unstructured":"Drilon A.; Cappuzzo F.; Ou S. H. I.; Camidge D. R.; Targeting MET in lung cancer: Will expectations finally be met?. J Thorac Oncol  2017,12(1),15-26","journal-title":"J Thorac Oncol"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/jnci\/dji055","volume":"97","author":"Shigematsu H.","year":"2005","unstructured":"Shigematsu H.; Lin L.; Takahashi T.; Nomura M.; Suzuki M.; Wistuba I.I.; Fong K.M.; Lee H.; Toyooka S.; Shimizu N.; Fujisawa T.; Feng Z.; Roth J.A.; Herz J.; Minna J.D.; Gazdar A.F.; Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.. J Natl Cancer Inst  2005,97(5),339-346","journal-title":"J Natl Cancer Inst"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1141478","volume":"316","author":"Engelman J. A.","year":"2007","unstructured":"Engelman J. A.; Zejnullahu K.; Mitsudomi T.; Song Y.; Hyland C.; Park J. O.; Lindeman N.; Gale C. M.; Zhao X.; Christensen J.; Kosaka T.; Holmes A. J.; Rogers A. M.; Cappuzzo F.; Mok T.; Lee C.; Johnson B. E.; Cantley L. C.; J\u00e4nne P. A.; MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science  2007,316(5827),1039-1043","journal-title":"Science"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1158\/2159-8290.CD-20-0116","volume":"10","author":"Yun J.","year":"2020","unstructured":"Yun J.; Lee S.H.; Kim S.Y.; Jeong S.Y.; Kim J.H.; Pyo K.H.; Park C.W.; Heo S.G.; Yun M.R.; Lim S.; Lim S.M.; Hong M.H.; Kim H.R.; Thayu M.; Curtin J.C.; Knoblauch R.E.; Lorenzi M.V.; Roshak A.; Cho B.C.; Antitumor activity of amivantamab (Jnj-61186372), an egfr\u2013met bispecific antibody, in diverse models of egfr exon 20 insertion\u2013driven nsclc. Cancer Discov  2020,10(8),1194-1209","journal-title":"Cancer Discov"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1200\/JCO.21.00662","volume":"39","author":"Park K.","year":"2021","unstructured":"Park K.; Haura E.B.; Leighl N.B.; Mitchell P.; Shu C.A.; Girard N.; Viteri S.; Han J.Y.; Kim S.W.; Lee C.K.; Sabari J.K.; Spira A.I.; Yang T.Y.; Kim D.W.; Lee K.H.; Sanborn R.E.; Trigo J.; Goto K.; Lee J.S.; Yang J.C.H.; Govindan R.; Bauml J.M.; Garrido P.; Krebs M.G.; Reckamp K.L.; Xie J.; Curtin J.C.; Haddish-Berhane N.; Roshak A.; Millington D.; Lorenzini P.; Thayu M.; Knoblauch R.E.; Cho B.C.; Amivantamab in egfr exon 20 insertion- mutated non-small-cell lung cancer progressing on platinum chemotherapy: Initial results from the chrysalis phase i study. J Clin Oncol  2021,39(30),3391-3402","journal-title":"J Clin Oncol"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"8510","DOI":"10.1200\/JCO.2021.39.15_suppl.8510","volume":"39","author":"Owonikoko T. K.","year":"2021","unstructured":"Owonikoko T. K.; Champiat S.; Johnson M. L.; Govindan R.; Izumi H.; Lai W. V. V.; Borghaei H.; Boyer M. J.; Boosman R. J.; Hummel H-D.; Blackhall F. H.; Reguart N.; Dowlati A.; Zhang Y.; Mukherjee S.; Minocha M.; Zhou Y.; Shetty A.; Hashemi Sadraei N.; Paz-Ares L. G.; Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC). J Clin Oncol  2021,39(15_suppl),8510-8510","journal-title":"J Clin Oncol"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"TPS8603","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8603","volume":"40","author":"Ramalingam S. S.","year":"2022","unstructured":"Ramalingam S. S.; Ahn M-J.; Akamatsu H.; Blackhall F. H.; Borghaei H.; Hummel H-D.; Johnson M. L.; Reck M.; Zhang Y.; Jandial D.; Cheng S.; Paz-Ares L. G.; Phase 2 study of tarlatamab, a DLL3-targeting, half life\u2013extended, bispecific T-cell engager (HLE BiTE) immuno-oncology therapy, in relapsed\/refractory small cell lung cancer (SCLC). J Clin Oncol  2022,40(16_suppl),TPS8603-TPS8603","journal-title":"J Clin Oncol"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"Hellmann M.D.","year":"2019","unstructured":"Hellmann M.D.; Paz-Ares L.; Bernabe Caro R.; Zurawski B.; Kim S.W.; Carcereny Costa E.; Park K.; Alexandru A.; Lupinacci L.; de la Mora Jimenez E.; Sakai H.; Albert I.; Vergnenegre A.; Peters S.; Syrigos K.; Barlesi F.; Reck M.; Borghaei H.; Brahmer J.R.; O'Byrne K.J.; Geese W.J.; Bhagavatheeswaran P.; Rabindran S.K.; Kasinathan R.S.; Nathan F.E.; Ramalingam S.S.; Nivolumab plus Ipilimumab in advanced non\u2013small-cell lung cancer. N Engl J Med  2019,381(21),2020-2031","journal-title":"N Engl J Med"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1200\/JCO.22.01503","volume":"41","author":"Brahmer J. R.","year":"2023","unstructured":"Brahmer J. R.; Lee J. S.; Ciuleanu T. E.; Bernabe Caro R.; Nishio M.; Urban L.; Audigier-Valette C.; Lupinacci L.; Sangha R.; Pluzanski A.; Burgers J.; Mahave M.; Ahmed S.; Schoenfeld A. J.; Paz-Ares L. G.; Reck M.; Borghaei H.; O'Byrne K. J.; Gupta R. G.; Bushong J.; Li L.; Blum S. I.; Eccles L. J.; Ramalingam S. S.; Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non\u2013small-cell lung cancer in checkmate 227. J Clin Oncol  2023,41(6),1200-1212","journal-title":"J Clin Oncol"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","volume":"18","author":"Hellmann M.D.","year":"2017","unstructured":"Hellmann M.D.; Rizvi N.A.; Goldman J.W.; Gettinger S.N.; Borghaei H.; Brahmer J.R.; Ready N.E.; Gerber D.E.; Chow L.Q.; Juergens R.A.; Shepherd F.A.; Laurie S.A.; Geese W.J.; Agrawal S.; Young T.C.; Li X.; Antonia S.J.; Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): Results of an open-label, phase 1, multicohort study.. Lancet Oncol  2017,18(1),31-41","journal-title":"Lancet Oncol"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.annonc.2021.09.011","volume":"33","author":"Peters S.","year":"2022","unstructured":"Peters S.; Pujol J.L.; Dafni U.; D\u00f3mine M.; Popat S.; Reck M.; Andrade J.; Becker A.; Moro-Sibilot D.; Curioni-Fontecedro A.; Molinier O.; Nackaerts K.; Insa Moll\u00e1 A.; Gervais R.; L\u00f3pez Vivanco G.; Madelaine J.; Mazieres J.; Faehling M.; Griesinger F.; Majem M.; Gonz\u00e1lez Larriba J.L.; Provencio Pulla M.; Vervita K.; Roschitzki-Voser H.; Ruepp B.; Mitchell P.; Stahel R.A.; Le Pechoux C.; De Ruysscher D.; Stahel R.; Hiltbrunner A.; Pardo-Contreras M.; Gasca-Ruchti A.; Giacomelli N.; Kammler R.; Marti N.; Pfister R.; Piguet A.C.; Roux S.; Troesch S.; Schneider M.; Schweri R.; Zigomo I.; Tsourti Z.; Zygoura P.; Tsouprou S.; Kassapian M.; Vervita K.; Dimopoulou G.; Andriakopoulou C.; Morin F.; Amour E.; Mariaule G.; Archirel N.; Fernandez M.; Pereira E.; Benito L.; Lopez K.; Hern\u00e1ndez A.; Chinchen S.; Jurkovic H.; Livingstone A.; Mitchell J.; Walker M.; Mitchell P.; Ng S.; Steer C.; Briscoe K.; Saqib A.; Abdi E.; Houghton B.; O'Byrne K.; Chittajallu B.R.; Hughes B.G.; Black A.; Nackaerts K.; Werner H.; Gervais R.; Zalcman G.; Vaylet F.; Merle P.; Monnet I.; Moro-Sibilot D.; Molinier O.; Girard N.; Souquet P-J.; Barlesi F.; Debieuvre D.; Senellart H.; Poudenx M.; Dixmier A.; Pouessel D.; Cadranel J.; Lena H.; Quoix E.; Friard S.; Audigier-Valette C.; Mazieres J.; Pichon E.; Faehling M.; Kokowski K.; Kirchen H.; Griesinger F.; Tufman A.; De-Colle C.; de Langen J.; Gonz\u00e1lez Larriba J.L.; Insa A.; Majem M.; Massut\u00ed B.; Pulla M.P.; Aix S.P.; Villanueva N.; Vivanco G.L.; Andrade J.; Curioni-Fontecedro A.; Franks K.; Califano R.; Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy \u2013 Results from the randomised phase II ETOP\/IFCT 4-12 STIMULI trial.. Ann Oncol  2022,33(1),67-79","journal-title":"Ann Oncol"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1200\/JCO.18.01042","volume":"37","author":"Ready N.","year":"2019","unstructured":"Ready N.; Hellmann M. D.; Awad M. M.; Otterson G. A.; Gutierrez M.; Gainor J. F.; Borghaei H.; Jolivet J.; Horn L.; Mates M.; Brahmer J.; Rabinowitz I.; Reddy P. S.; Chesney J.; Orcutt J.; Spigel D. R.; Reck M.; O'Byrne K. J.; Paz-Ares L.; Hu W.; Zerba K.; Li X.; Lestini B.; Geese W. J.; Szustakowski J. D.; Green G.; Chang H.; Ramalingam S. S.; First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): Outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers.. J Clin Oncol  2019,37(12),992-1000","journal-title":"J Clin Oncol"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S1470-2045(15)00544-6","volume":"17","author":"Antonia S.","year":"2016","unstructured":"Antonia S.; Goldberg S.B.; Balmanoukian A.; Chaft J.E.; Sanborn R.E.; Gupta A.; Narwal R.; Steele K.; Gu Y.; Karakunnel J.J.; Rizvi N.A.; Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: A multicentre, phase 1b study. Lancet Oncol  2016,17(3),299-308","journal-title":"Lancet Oncol"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1001\/jamaoncol.2020.0237","volume":"6","author":"Rizvi N. A.","year":"2020","unstructured":"Rizvi N. A.; Cho B. C.; Reinmuth N.; Lee K. H.; Luft A.; Ahn M. J.; van den Heuvel M. M.; Cobo M.; Vicente D.; Smolin A.; Moiseyenko V.; Antonia S. J.; Le Moulec S.; Robinet G.; Natale R.; Schneider J.; Shepherd F. A.; Geater S. L.; Garon E. B.; Kim E. S.; Goldberg S. B.; Nakagawa K.; Raja R.; Higgs B. W.; Boothman A. M.; Zhao L.; Scheuring U.; Stockman P. K.; Chand V. K.; Peters S.; Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non\u2013small cell lung cancer. JAMA Oncol  2020,6(5),661-674","journal-title":"JAMA Oncol"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s12672-025-01902-y","volume":"16","author":"Arandhara A.","year":"2025","unstructured":"Arandhara A.; Bhuyan P.; Das B. K.; Exploring lung cancer microenvironment: Pathways and nanoparticle-based therapies.. Disc Oncol  2025,16(1),159","journal-title":"Disc Oncol"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.3390\/cancers13122924","volume":"13","author":"Chi A.","year":"2021","unstructured":"Chi A.; He X.; Hou L.; Nguyen N.P.; Zhu G.; Cameron R.B.; Lee J.M.; Classification of non-small cell lung cancer\u2019s tumor immune micro-environment and strategies to augment its response to immune checkpoint blockade. Cancers  2021,13(12),2924","journal-title":"Cancers"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41568-018-0081-9","volume":"19","author":"Altorki N. K.","year":"2019","unstructured":"Altorki N. K.; Markowitz G. J.; Gao D.; Port J. L.; Saxena A.; Stiles B.; McGraw T.; Mittal V.; The lung microenvironment: An important regulator of tumour growth and metastasis.. Nat Rev Cancer  2019,19(1),9-31","journal-title":"Nat Rev Cancer"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"1802540","DOI":"10.1002\/adfm.201802540","volume":"28","author":"Fan Q.","year":"2018","unstructured":"Fan Q.; Chen Z.; Wang C.; Liu Z.; Toward biomaterials for enhancing immune checkpoint blockade therapy. Adv Funct Mater  2018,28(37),1802540","journal-title":"Adv Funct Mater"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1186\/s12951-024-03005-2","volume":"22","author":"Feng Y.","year":"2024","unstructured":"Feng Y.; Tang Q.; Wang B.; Yang Q.; Zhang Y.; Lei L.; Li S.; Targeting the tumor microenvironment with biomaterials for enhanced immunotherapeutic efficacy. J Nanobiotechnol  2024,22(1),737","journal-title":"J Nanobiotechnol"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.2147\/IJN.S505539","volume":"20","author":"Ge Y.","year":"2025","unstructured":"Ge Y.; Zhou Q.; Pan F.; Wang R.; Utilizing nanoparticles to overcome anti-PD-1\/PD-L1 immunotherapy resistance in non-small cell lung cancer: A potential strategy. Int J Nanomed  2025,20,2371-2394","journal-title":"Int J Nanomed"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"948","DOI":"10.20892\/j.issn.2095-3941.2022.0049","volume":"19","author":"Wang W.","year":"2022","unstructured":"Wang W.; Zhang L.; Sun Z.; Eliciting pyroptosis to fuel cancer immunotherapy: Mechanisms and strategies. Cancer Biol Med  2022,19(7),948-964","journal-title":"Cancer Biol Med"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41392-022-01046-3","volume":"7","author":"Gao W.","year":"2022","unstructured":"Gao W.; Wang X.; Zhou Y.; Wang X.; Yu Y.; Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy. Signal Transduct Target Ther  2022,7(1),196","journal-title":"Signal Transduct Target Ther"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13045-020-00946-7","volume":"13","author":"Tang R.","year":"2020","unstructured":"Tang R.; Xu J.; Zhang B.; Liu J.; Liang C.; Hua J.; Meng Q.; Yu X.; Shi S.; Ferroptosis, necroptosis, and pyroptosis in anticancer immunity.. J Hematol Oncol  2020,13(1),110","journal-title":"J Hematol Oncol"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1007\/s12325-019-01051-z","volume":"36","author":"Arora S.","year":"2019","unstructured":"Arora S.; Velichinskii R.; Lesh R.W.; Ali U.; Kubiak M.; Bansal P.; Borghaei H.; Edelman M.J.; Boumber Y.; Existing and emerging biomarkers for immune checkpoint immunotherapy in solid tumors.. Adv Ther  2019,36(10),2638-2678","journal-title":"Adv Ther"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"S308","DOI":"10.21037\/tlcr.2019.08.02","volume":"8","author":"Liu S. Y.","year":"2019","unstructured":"Liu S. Y.; Wu Y. L.; Biomarker for personalized immunotherapy. Transl Lung Cancer Res  2019,8(S3),S308-S317","journal-title":"Transl Lung Cancer Res"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41571-019-0173-9","volume":"16","author":"Camidge D.R.","year":"2019","unstructured":"Camidge D.R.; Doebele R.C.; Kerr K.M.; Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nat Rev Clin Oncol  2019,16(6),341-355","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","volume":"22","author":"Lahiri A.","year":"2023","unstructured":"Lahiri A.; Maji A.; Potdar P. D.; Singh N.; Parikh P.; Bisht B.; Mukherjee A.; Paul M. K.; Lung cancer immunotherapy: Progress, pitfalls, and promises. Mol Cancer  2023,22(1),40","journal-title":"Mol Cancer"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.2217\/bmm-2020-0310","volume":"14","author":"C Guven D.","year":"2020","unstructured":"C Guven D.; Sahin T. K.; Dizdar O.; Kilickap S.; Predictive biomarkers for immunotherapy efficacy in non-small-cell lung cancer: Current status and future perspectives.. Biomarkers Med  2020,14(14),1383-1392","journal-title":"Biomarkers Med"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.3892\/OL.2019.10166\/DOWNLOAD","volume":"17","author":"Cai L. L.","year":"2019","unstructured":"Cai L. L.; Wang J.; Liquid biopsy for lung cancer immunotherapy. Oncol Lett  2019,17(6),4751-4760","journal-title":"Oncol Lett"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.3390\/cancers13081794","volume":"13","author":"Indini A.","year":"2021","unstructured":"Indini A.; Rijavec E.; Grossi F.; Circulating biomarkers of response and toxicity of immunotherapy in advanced non-small cell lung cancer (NSCLC): A comprehensive review.. Cancers  2021,13(8),1794","journal-title":"Cancers"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"1249980","DOI":"10.3389\/fimmu.2023.1249980","volume":"14","author":"Liang S.","year":"2023","unstructured":"Liang S.; Wang H.; Tian H.; Xu Z.; Wu M.; Hua D.; Li C.; The prognostic biological markers of immunotherapy for non-small cell lung cancer: Current landscape and future perspective.. Front Immunol  2023,14,1249980","journal-title":"Front Immunol"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"000631","DOI":"10.1136\/esmoopen-2019-000631","volume":"5","author":"Han S.","year":"2020","unstructured":"Han S.; Shuen W. H.; Wang W. W.; Nazim E.; Toh H. C.; Tailoring precision immunotherapy: Coming to a clinic soon?. ESMO Open  2020,5(Suppl 1),000631","journal-title":"ESMO Open"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"102917","DOI":"10.1016\/j.esmoop.2024.102917","volume":"9","author":"Horne A.","year":"2024","unstructured":"Horne A.; Crawford H.; Dempsey C.; Faivre-Finn C.; 162TiP An update on the VIGILANCE study: Developing circulating and imaging biomarkers towards personalised radiotherapy in lung cancer. ESMO Open  2024,9,102917","journal-title":"ESMO Open"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3390\/cancers16071440","volume":"16","author":"Casagrande S.","year":"2024","unstructured":"Casagrande S.; Sopetto G. B.; Bertalot G.; Bortolotti R.; Racanelli V.; Caffo O.; Giometto B.; Berti A.; Veccia A.; Immune-related adverse events due to cancer immunotherapy: Immune mechanisms and clinical manifestations.. Cancers  2024,16(7),1440","journal-title":"Cancers"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","volume":"33","author":"Gettinger S. N.","year":"2015","unstructured":"Gettinger S. N.; Horn L.; Gandhi L.; Spigel D. R.; Antonia S. J.; Rizvi N. A.; Powderly J. D.; Heist R. S.; Carvajal R. D.; Jackman D. M.; Sequist L. V.; Smith D. C.; Leming P.; Carbone D. P.; Pinder-Schenck M. C.; Topalian S. L.; Hodi F. S.; Sosman J. A.; Sznol M.; McDermott D. F.; Pardoll D. M.; Sankar V.; Ahlers C. M.; Salvati M.; Wigginton J. M.; Hellmann M. D.; Kollia G. D.; Gupta A. K.; Brahmer J. R.; Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol  2015,33(18),2004-2012","journal-title":"J Clin Oncol"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/cncr.31043","volume":"124","author":"Pillai R. N.","year":"2018","unstructured":"Pillai R. N.; Behera M.; Owonikoko T. K.; Kamphorst A. O.; Pakkala S.; Belani C. P.; Khuri F. R.; Ahmed R.; Ramalingam S. S.; Comparison of the toxicity profile of PD\u20101 versus PD\u2010L1 inhibitors in non\u2013small cell lung cancer: A systematic analysis of the literature. Cancer  2018,124(2),271-277","journal-title":"Cancer"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s11739-020-02295-2","volume":"15","author":"de La Rochefoucauld J.","year":"2020","unstructured":"de La Rochefoucauld J.; No\u00ebl N.; Lambotte O.; Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: A patient-centred approach.. Intern Emerg Med  2020,15(4),587-598","journal-title":"Intern Emerg Med"},{"key":"ref=213","doi-asserted-by":"publisher","first-page":"720759","DOI":"10.3389\/fonc.2021.720759","volume":"11","author":"Burke M.","year":"2021","unstructured":"Burke M.; Rashdan S.; Management of immune-related adverse events in patients with non-small cell lung cancer. Front Oncol  2021,11,720759","journal-title":"Front Oncol"},{"key":"ref=214","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2147\/TCRM.S479686","volume":"21","author":"Boucheron T.","year":"2025","unstructured":"Boucheron T.; Chiche L.; Penaranda G.; Souquet M.; Pegliasco H.; Deturmeny J.; Brunel V.; Barri\u00e8re N.; Arbault-Bitton C.; Coquet E.; Diaz L.; Escoda T.; Risk of serious immune-related adverse events with various PD1 and PD-L1 inhibitors: A single-institution, real-life, comparative study.. Ther Clin Risk Manag  2025,21,273-282","journal-title":"Ther Clin Risk Manag"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"S1516","DOI":"10.21037\/jtd.2017.12.52","volume":"10","author":"Remon J.","year":"2018","unstructured":"Remon J.; Mezquita L.; Corral J.; Vilari\u00f1o N.; Reguart N.; Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: Focusing on non-small cell lung cancer patients.. J Thorac Dis  2018,10(Suppl 13),S1516-S1533","journal-title":"J Thorac Dis"},{"key":"ref=216","doi-asserted-by":"publisher","first-page":"703893","DOI":"10.3389\/fonc.2021.703893","volume":"11","author":"Daniello L.","year":"2021","unstructured":"Daniello L.; Elshiaty M.; Bozorgmehr F.; Kuon J.; Kazdal D.; Schindler H.; Shah R.; Volckmar A.L.; Lusky F.; Diekmann L.; Liersch S.; Faehling M.; Muley T.; Kriegsmann M.; Benesova K.; Stenzinger A.; Thomas M.; Christopoulos P.; Therapeutic and prognostic implications of immune-related adverse events in advanced non-small-cell lung cancer.. Front Oncol  2021,11,703893","journal-title":"Front Oncol"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"790","DOI":"10.3390\/biomedicines10040790","volume":"10","author":"Vaddepally R.","year":"2022","unstructured":"Vaddepally R.; Doddamani R.; Sodavarapu S.; Madam N. R.; Katkar R.; Kutadi A. P.; Mathew N.; Garje R.; Chandra A. B.; Review of immune-related adverse events (irAEs) in non-small-cell lung cancer (NSCLC)\u2014Their incidence, management, Multiorgan irAEs, and Rechallenge. Biomedicines  2022,10(4),790","journal-title":"Biomedicines"},{"key":"ref=218","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s00262-021-03045-9","volume":"71","author":"Russano M.","year":"2022","unstructured":"Russano M.; Cortellini A.; Giusti R.; Russo A.; Zoratto F.; Rastelli F.; Gelibter A.; Chiari R.; Nigro O.; De Tursi M.; Bracarda S.; Gori S.; Grossi F.; Bersanelli M.; Calvetti L.; Di Noia V.; Scartozzi M.; Di Maio M.; Bossi P.; Falcone A.; Citarella F.; Pantano F.; Ficorella C.; Filetti M.; Adamo V.; Veltri E.; Pergolesi F.; Occhipinti M. A.; Nicolardi L.; Tuzi A.; Di Marino P.; Macrini S.; Inno A.; Ghidini M.; Buti S.; Aprile G.; Lai E.; Audisio M.; Intagliata S.; Marconcini R.; Brocco D.; Porzio G.; Piras M.; Rijavec E.; Simionato F.; Natoli C.; Tiseo M.; Vincenzi B.; Tonini G.; Santini D.; Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1\/PD-L1 checkpoint inhibitors leading to treatment discontinuation.. Cancer Immunol Immunother  2022,71(4),865-874","journal-title":"Cancer Immunol Immunother"},{"key":"ref=219","doi-asserted-by":"publisher","first-page":"e2352302","DOI":"10.1001\/jamanetworkopen.2023.52302","volume":"7","author":"Cook S.","year":"2024","unstructured":"Cook S.; Samuel V.; Meyers D.E.; Stukalin I.; Litt I.; Sangha R.; Morris D.G.; Heng D.Y.C.; Pabani A.; Dean M.; Navani V.; Immune-related adverse events and survival among patients with metastatic NSCLC treated with immune checkpoint inhibitors. JAMA Netw Open  2024,7(1),e2352302-e2352302","journal-title":"JAMA Netw Open"},{"key":"ref=220","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.3390\/cancers14163878","volume":"14","author":"Guezour N.","year":"2022","unstructured":"Guezour N.; Soussi G.; Brosseau S.; Abbar B.; Naltet C.; Vauchier C.; Pot\u00e9 N.; Hachon L.; Namour C.; Khalil A.; Tr\u00e9daniel J.; Zalcman G.; Gounant V.; Grade 3\u20134 immune-related adverse events induced by immune checkpoint inhibitors in non-small-cell lung cancer (NSCLC) patients are correlated with better outcome: A real-life observational study. Cancers  2022,14(16),3878","journal-title":"Cancers"},{"key":"ref=221","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","volume":"6","author":"Shankar B.","year":"2020","unstructured":"Shankar B.; Zhang J.; Naqash A.R.; Forde P.M.; Feliciano J.L.; Marrone K.A.; Ettinger D.S.; Hann C.L.; Brahmer J.R.; Ricciuti B.; Owen D.; Toi Y.; Walker P.; Otterson G.A.; Patel S.H.; Sugawara S.; Naidoo J.; Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non\u2013small cell lung cancer. JAMA Oncol  2020,6(12),1952-1956","journal-title":"JAMA Oncol"},{"key":"ref=222","doi-asserted-by":"publisher","first-page":"1519082","DOI":"10.3389\/fphar.2025.1519082","volume":"16","author":"Yan T.","year":"2025","unstructured":"Yan T.; Long M.; Liu C.; Zhang J.; Wei X.; Li F.; Liao D.; Immune-related adverse events with PD-1\/PD-L1 inhibitors: Insights from a real-world cohort of 2523 patients. Front Pharmacol  2025,16,1519082","journal-title":"Front Pharmacol"},{"key":"ref=223","doi-asserted-by":"publisher","DOI":"10.1101\/2021.11.30.21267064","author":"Benzekry S.","year":"2021","unstructured":"Benzekry S.; Grangeon M.; Karlsen M.; Alexa M.; Bicalho-Frazeto I.; Chaleat S.; Tomasini P.; Barbolosi D.; Barlesi F.; Greillier L.; Machine learning for prediction of immunotherapy efficacy in non-small cell lung cancer from simple clinical and biological data. medRxiv  2021","journal-title":"medRxiv"},{"key":"ref=224","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-023-01456-y","volume":"16","author":"Gao Q.","year":"2023","unstructured":"Gao Q.; Yang L.; Lu M.; Jin R.; Ye H.; Ma T.; The artificial intelligence and machine learning in lung cancer immunotherapy. J Hematol Oncol  2023,16(1),55","journal-title":"J Hematol Oncol"},{"key":"ref=225","doi-asserted-by":"publisher","first-page":"009721","DOI":"10.1136\/jitc-2024-009721","volume":"12","author":"Bao R.","year":"2024","unstructured":"Bao R.; Hutson A.; Madabhushi A.; Jonsson V.D.; Rosario S.R.; Barnholtz-Sloan J.S.; Fertig E.J.; Marathe H.; Harris L.; Altreuter J.; Chen Q.; Dignam J.; Gentles A.J.; Gonzalez-Kozlova E.; Gnjatic S.; Kim E.; Long M.; Morgan M.; Ruppin E.; Valen D.V.; Zhang H.; Vokes N.; Meerzaman D.; Liu S.; Van Allen E.M.; Xing Y.; Ten challenges and opportunities in computational immuno-oncology. J Immunother Cancer  2024,12(10),009721","journal-title":"J Immunother Cancer"},{"key":"ref=226","doi-asserted-by":"publisher","first-page":"893198","DOI":"10.3389\/fimmu.2022.893198","volume":"13","author":"Cheng G.","year":"2022","unstructured":"Cheng G.; Zhang F.; Xing Y.; Hu X.; Zhang H.; Chen S.; Li M.; Peng C.; Ding G.; Zhang D.; Chen P.; Xia Q.; Wu M.; Artificial Intelligence-assisted score analysis for predicting the expression of the immunotherapy biomarker PD-L1 in lung cancer. Front Immunol  2022,13,893198","journal-title":"Front Immunol"},{"key":"ref=227","doi-asserted-by":"publisher","first-page":"1485703","DOI":"10.3389\/fimmu.2024.1485703","volume":"15","author":"Liu J.","year":"2024","unstructured":"Liu J.; Sun D.; Xu S.; Shen J.; Ma W.; Zhou H.; Ma Y.; Zhang Y.; Fang W.; Zhao Y.; Hong S.; Zhan J.; Hou X.; Zhao H.; Huang Y.; He B.; Yang Y.; Zhang L.; Association of artificial intelligence-based immunoscore with the efficacy of chemoimmunotherapy in patients with advanced non-squamous non-small cell lung cancer: A multicentre retrospective study. Front Immunol  2024,15,1485703","journal-title":"Front Immunol"},{"key":"ref=228","doi-asserted-by":"publisher","first-page":"1024707","DOI":"10.3389\/fimmu.2022.1024707","volume":"13","author":"Li S.","year":"2022","unstructured":"Li S.; Li W.; Ma T.; Fu S.; Gao X.; Qin N.; Wu Y.; Zhang X.; Wang J.; Pan Y.; Liu Z.; Assessing the efficacy of immunotherapy in lung squamous carcinoma using artificial intelligence neural network. Front Immunol  2022,13,1024707","journal-title":"Front Immunol"},{"key":"ref=229","first-page":"743","volume":"13","author":"Yang Y.","year":"2021","unstructured":"Yang Y.; Yang J.; Shen L.; Chen J.; Xia L.; Ni B.; Ge L.; Wang Y.; Lu S.; A multi-omics-based serial deep learning approach to predict clinical outcomes of single-agent anti-PD-1\/PD-L1 immunotherapy in advanced stage non-small-cell lung cancer. Am J Transl Res  2021,13(2),743-756","journal-title":"Am J Transl Res"},{"key":"ref=230","doi-asserted-by":"publisher","first-page":"007841","DOI":"10.1136\/jitc-2023-007841","volume":"12","author":"Bottomly D.","year":"2024","unstructured":"Bottomly D.; McWeeney S.; Just how transformative will AI\/ML be for immuno-oncology?. J Immunother Cancer  2024,12(3),007841","journal-title":"J Immunother Cancer"},{"key":"ref=231","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12943-025-02321-x","volume":"24","author":"Mao Y.","year":"2025","unstructured":"Mao Y.; Shangguan D.; Huang Q.; Xiao L.; Cao D.; Zhou H.; Wang Y.K.; Emerging artificial intelligence-driven precision therapies in tumor drug resistance: Recent advances, opportunities, and challenges. Mol Cancer  2025,24(1),123","journal-title":"Mol Cancer"},{"key":"ref=232","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/diseases13010024","volume":"13","author":"Olawade D. B.","year":"2025","unstructured":"Olawade D. B.; Clement David-Olawade A.; Adereni T.; Egbon E.; Teke J.; Boussios S.; Integrating AI into cancer immunotherapy\u2014A narrative review of current applications and future directions. Diseases  2025,13(1),24","journal-title":"Diseases"},{"key":"ref=233","doi-asserted-by":"publisher","first-page":"2435598","DOI":"10.1080\/21645515.2024.2435598","volume":"21","author":"Qiao Y.","year":"2025","unstructured":"Qiao Y.; Xie D.; Li Z.; Cao S.; Zhao D.; Global research trends on biomarkers for cancer immunotherapy: Visualization and bibliometric analysis. Hum Vaccin Immunother  2025,21(1),2435598","journal-title":"Hum Vaccin Immunother"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113895575415429251007093531","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/247001\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113895575415429251007093531","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T09:34:06Z","timestamp":1785144846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/247001\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":233,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113895575415429251007093531","relation":{},"ISSN":["1389-5575"],"issn-type":[{"value":"1389-5575","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-05-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}